Central 5-HT receptors and their function; present and future

Sharp, Trevor; Barnes, Nicholas M.

DOI:

[10.1016/j.neuropharm.2020.108155](https://doi.org/10.1016/j.neuropharm.2020.108155)

License:

Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)

Document Version

Peer reviewed version

Citation for published version (Harvard):

Sharp, T & Barnes, NM 2020, 'Central 5-HT receptors and their function; present and future', *Neuropharmacology*, vol. 177, 108155. <https://doi.org/10.1016/j.neuropharm.2020.108155>

[Link to publication on Research at Birmingham portal](#)

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Central 5-HT receptors and their function; present and future

Trevor Sharp and ¹Nicholas M. Barnes

University Department of Pharmacology, Mansfield Road,
Oxford OX1 3QT and ¹Institute of Clinical Sciences,
University of Birmingham, Birmingham B15 2TT

Abstract

Since our review of central 5-HT receptors and their function twenty years ago, no new 5-HT receptors have been discovered and there is little evidence that this situation will change in the near future. Nevertheless, over this time significant progress has been made in our understanding of the properties of these receptors and in the clinical translation of this information, and some of these developments are highlighted herein. Such highlights include extensive mapping of 5-HT receptors in both animal and human brain, culminating in readily-accessible brain atlases of 5-HT receptor distribution, as well as emerging data on how 5-HT receptors are distributed within complex neural circuits. Also, a range of important pharmacological and genetic tools have been developed that allow selective 5-HT receptor manipulation, in cells through to whole organism models. Moreover, unexpected complexity in 5-HT receptor function has been identified including agonist-dependent signalling that goes beyond the pharmacology of canonical 5-HT receptor signalling pathways set down in the 1980s and 1990s. This new knowledge of 5-HT signalling has been extended by the discovery of combined signalling of 5-HT and co-released neurotransmitters, especially glutamate. Another important advance has been the progression of a large number of 5-HT ligands through to experimental medicine studies and clinical trials, and some such agents have already become prescribed therapeutic drugs. Much more needs to be discovered and understood by 5-HT neuropharmacologists, not least how the diverse signalling effects of so many 5-HT receptor types interact with complex neural circuits to generate neurophysiological changes which ultimately lead to altered cognitions and behaviour.

1. Introduction

Following the initial identification of two types of 5-HT receptor in peripheral tissue sixty years ago, 'D' and 'M' 5-HT receptors (Gaddum & Picarelli, 1957), a combination of pharmacological and then molecular biological investigations led to the discovery of an unexpected diversity of 5-HT receptor types. An excellent account of the history of 5-HT receptor discovery and classification is given by Bockaert and colleagues (Bockaert *et al.*, 2010). The current consensus is that the brain expresses 7 types of 5-HT receptors (5-HT₁₋₇) comprising a total of 14 subtypes (Figure 1) although 2 of these receptors, 5-HT_{1e} and 5-HT_{5b}, retain lower case appellation and are still classed as gene products since they have not yet been linked to a functional response in native cells/tissues. All 5-HT receptor subtypes are found in both brain and peripheral tissues with the exception of 5-HT_{1e}, 5-HT_{2C} and 5-HT₆ receptors, for which there is limited expression outside the CNS. Also, multiple isoforms of certain 5-HT receptors (notably 5-HT_{2C}, 5-HT₃, 5-HT₄ and 5-HT₇ receptors) have been reported, but the pharmacological and functional significance of this diversity remains uncertain. This receptor diversity is comparable to that of the most complex neurotransmitter systems including glutamate and purines. Despite this complexity, a wide range of selective agonists, antagonists and radioligands are now available to target specific 5-HT receptor subtypes (summarized in Table 1) and probe their localisation, signalling properties, and CNS function.

In the human genome, the 5-HT receptor subtypes are coded by 17 genes, with 12 encoding metabotropic 5-HT receptors and 5 encoding subunits for ionotropic 5-HT₃ receptors (an additional sequence in the human genome corresponds to the 5-HT_{5b} receptor in some other species, although the presence of stop codons in the human gene prevents full length protein expression). The genes encoding 5-HT receptors (and the 5-HT transporter) demonstrate polymorphisms in coding and non-coding regions, which are often common in the human population. However, despite many reports of associations between specific 5-HT receptor gene polymorphisms and particular neuropsychiatric disorders, as with the vast majority of such gene-associations, effect sizes are typically modest and findings await replication in large scale datasets. This work is now expanding to incorporate findings of epigenetic regulation of 5-HT receptors which might provide a

clearer picture of how natural variation in 5-HT receptor genes links to CNS disorder. Consequently, the importance of variability in 5-HT receptor (and 5-HT transporter) genes as mental health risk factors currently remains uncertain, and detailed analysis and review is warranted.

2. 5-HT receptor signalling

2.1. Metabotropic 5-HT receptors: canonical signalling

Thirteen of the 14 5-HT receptor subtypes are classical metabotropic G-protein coupled receptors which couple to canonical signalling pathways, that elicit the expected second messenger cascades (Table 1). The 5-HT₁ receptor family, comprises 5-HT_{1A}, 5-HT_{1B}, 5-HT_{1D}, 5-HT_{1E}, and 5-HT_{1F} subtypes (5-HT_{1C} subsequently being re-designated 2-HT_{2C}; (Humphrey *et al.*, 1993), and these are G_i-coupled and inhibit adenylate cyclase and decrease cAMP formation (Masson *et al.*, 2012). These receptors also indirectly open G-protein-gated inwardly rectifying potassium channels (GIRKs) to hyperpolarise neurons, and inhibit the opening of voltage-gated calcium channels (eg. (Montalbano *et al.*, 2015). The 5-HT₅ receptor family, 5-HT_{5A} and 5-HT_{5B} (the full-length protein of the latter receptor is not expressed in humans), is also G_i-coupled, and 5-HT_{5A} receptor-mediated hyperpolarization was identified in cortical neurons (Goodfellow *et al.*, 2012).

In comparison, the 5-HT₂ receptor family, which comprises 5-HT_{2A}, 5-HT_{2B}, and 5-HT_{2C} receptor subtypes, is G_{q/11}-coupled and activates phospholipase C leading to increased formation of inositol trisphosphate and diacylglycerol, and the triggering of their downstream signalling events. 5-HT₂ receptor stimulation also results in neuronal excitation in a variety of brain regions, likely involving the closure of potassium channels and depolarisation. A 5-HT₂ receptor-mediated increase in excitatory postsynaptic currents is also often observed in *in vitro* preparations, which is thought to be mediated either directly or indirectly through increased release of glutamate (Lamb & Aghajanian, 2006; Marek, 2010). The remaining metabotropic 5-HT receptors, 5-HT₄, 5-HT₆, and 5-HT₇ receptors, are all excitatory with effects mediated through G_s-coupling, adenylate cyclase activation and increased cAMP formation. At the electrophysiological level, 5-HT₄ receptor

activation in neurons is associated with a slow membrane depolarization mediated by a reduction of a slow after-hyperpolarization potential, and facilitation of L-type calcium channels through protein kinase A activation (Andrade & Chaput, 1991; Birnstiel & Beck, 1995). Similarly, the 5-HT₆ receptor is reported to exert excitatory effects on specific neuron types (striatal cholinergic interneurons, hippocampal GABA interneurons) in recordings from brain slices (West *et al.*, 2009; Tassone *et al.*, 2010). Additionally, the 5-HT₇ receptor is associated with a direct depolarizing or excitatory effect, also likely mediated by actions on slow after-hyperpolarization and L-type calcium channels (Bacon & Beck, 2000; Andrade, 2006).

2.2. Metabotropic 5-HT receptors: non-canonical signalling

An intriguing aspect of metabotropic 5-HT receptor function is the discovery that they elicit non-canonical signals that can be either mediated by a host of alternative G-proteins, or be G-protein independent. This G-protein independent signalling often involves β -arrestins which, as signal transduction scaffolds, bring elements of other signaling pathways such as the mitogen-activated protein kinases including extracellular signal-regulated kinase (ERK), into close proximity. Moreover, there is growing evidence that different 5-HT receptor agonists interact with the same 5-HT receptor but preferentially activate specific intracellular signalling pathways, a property referred to as 'functional selectivity' or 'biased agonism'. A summary of the non-canonical signaling and biased agonism capabilities of different 5-HT receptor subtypes is provided in Table 2.

There is convincing evidence that the 5-HT_{1A} receptor signals not only via G_i-coupled adenylyl cyclase but also a variety of non-canonical pathways (Masson *et al.*, 2012; Albert & Vahid-Ansari, 2019). This includes the ERK signalling pathway which mediates a wide range of cellular responses ranging from structural changes to different forms of synaptic plasticity, as well as signalling via small G-proteins (eg. Rho A). This signalling diversity may in part connect with evidence that 5-HT_{1A} receptors couple to a diversity of G-proteins depending on their localisation within the brain (Mannoury la Cour *et al.*, 2006). It might also help explain long-standing evidence of presynaptic versus postsynaptic differences in 5-HT_{1A} receptor reserve and efficiency of G-protein coupling. This knowledge is currently being exploited to identify 5-HT_{1A} receptor biased

agonists that preferentially direct receptor signalling to particular intracellular pathways in a brain region-specific manner (Sniecikowska *et al.*, 2019). A number of 5-HT_{1A} receptor biased agonists are currently under investigation as potential novel CNS therapies as discussed later. Evidence that 5-HT_{1B} receptors are capable of non-canonical signaling via β -arrestin and other signaling pathways is also reported and reviewed elsewhere (Millan *et al.*, 2008; Liu *et al.*, 2019).

It is now recognised that 5-HT₂ receptor signalling (the 'D' receptor identified by Gaddum and Picarelli) also goes beyond the canonical G_{q/11}-coupled phospholipase C signalling pathway. Non-canonical signalling pathways associated with the 5-HT_{2A} receptor include phospholipase A₂, the ERK pathway, and the β -arrestin coupled *Src*/Akt cascade as recently reviewed (Bockaert *et al.*, 2010; Halberstadt, 2015; McCorvy & Roth, 2015; Maroteaux *et al.*, 2016). Both 5-HT_{2B} and 5-HT_{2C} receptors are reported to interact with a similar group of non-canonical signalling pathways (Labasque *et al.*, 2008), and contrasting agonist efficacies for different 5-HT_{2C} signaling pathways are reported (Berg *et al.*, 1998; Berg *et al.*, 2008; Millan *et al.*, 2008; Cheng *et al.*, 2016). Furthermore, recent studies of 5-HT_{2B} receptor evoked G-protein and β -arrestin signalling reported evidence of agonist-dependent signals (eg. LSD, ergotamine), and then used the crystal structure of the 5-HT_{2B} receptor to identify with high resolution, thereby providing details of the structural basis for this biased signalling and a rational basis for the discovery of 5-HT_{2B} receptor agonists without cardiac side-effects (Wacker *et al.*, 2013; McCorvy *et al.*, 2018b). Evidence of 5-HT_{2A} receptor biased agonism has relevance to the psychotropic effects of 5-HT_{2A} receptor agonists, most of which are hallucinogenic but apparently not all such as lisuride (Gonzalez-Maeso *et al.*, 2007). Thus, there is the interesting possibility of identifying 5-HT_{2A} receptor agonists without hallucinogenic properties and also, potentially, without effects on peripheral tissues such as vascular and other smooth muscle.

In addition to 5-HT₁ and 5-HT₂ receptors, the capacity for both canonical and non-canonical signalling is evident for other metabotropic 5-HT receptors, as detailed for 5-HT₄, 5-HT₆ and 5-HT₇ receptors in other reviews (Bockaert *et al.*, 2010; Masson *et al.*, 2012; Blattner *et al.*, 2019; Chaumont-Dubel *et al.*, 2019). These signaling pathways includes; ERK for 5-HT₄ receptors, ERK,

mTOR and Cdk5 for 5-HT₆ receptors, and ERK and small G-proteins for 5-HT₇ receptors. These data suggest that biased agonism is also likely to emerge as a property of these receptors. Indeed, evidence of agonist-dependent signalling at 5-HT₄ receptors (RS 67333, prucalopride) and 5-HT₇ receptors has recently been reported (Gaven *et al.*, 2013; Kim *et al.*, 2018; McCorvy *et al.*, 2018a).

It presently remains to be established how much of this 5-HT receptor signalling diversity is expressed in native neurons (as opposed to transfected cell cultures), and there is a need for validation in neurons and brain regions in which the 5-HT receptors are naturally expressed. Nevertheless, these developments raise the exciting prospect of designing drugs (biased agonists) to target a particular 5-HT receptor and elicit one or a small number of the many possible signalling pathways coupled to that same receptor. Thus, agonists with selectivity for evoking specific signaling effects via a particular receptor may offer therapeutic benefits over agonists that elicit multiple signaling effects via that receptor (eg. non-hallucigenic 5-HT_{2A} receptor agonists, cardiac side effect-free 5-HT_{2B} receptor agonists). Linking specific 5-HT receptor-induced signalling effects to specific functional/behavioural effects will be challenging and require not only biased agonists but also cell- and animal-based models expressing 5-HT receptors with modified signalling capabilities. One approach would be the knock-in of mutated 5-HT receptors which have limited capacity to signal via a particular pathway, as recently reported for the 5-HT_{2B} receptor (McCorvy *et al.*, 2018b).

Another intriguing aspect of this potential for the triggering of multiple pathways by individual 5-HT receptors, is its possible physiological purpose. This differential signaling may translate into different behavioural and cognitive effects (see above), and might also reflect a capacity for signalling over different temporal scales (eg. short-term synaptic effects of ion channel modulation versus enduring effects of gene expression) and spatial scales (neuron type, brain region), and at different stages of development. In regard to the latter, it is notable that certain signalling pathways (eg. Rho A, mTOR, Cdk5) linked to particular 5-HT receptors (eg. 5-HT_{1A}, 5-HT₆, 5-HT₇) mediate changes in neuronal architecture (neurite, synapse and neural circuit formation) and placement (neuronal migration). These signalling effects are likely to be associated with the long recognized

neurotrophic and neurodevelopmental role of 5-HT (Daubert & Condron, 2010; Teissier *et al.*, 2017).

Aside from canonical and non-canonical pathways, further complexity in metabotropic 5-HT receptor signalling arises from the large number of protein partners that have been found to influence cellular localization and trafficking of these receptors, and also alter receptor function through homo- or heterodimerization with other GPCRs, as noted in recent reviews (Hannon & Hoyer, 2008; Bockaert *et al.*, 2010; McCorvy & Roth, 2015; Chaumont-Dubel *et al.*, 2019). Alternative RNA splicing and editing is reported to generate multiple isoforms of certain metabotropic 5-HT receptors (especially 5-HT_{2C}, 5-HT₄ and 5-HT₇ receptors). Although the pharmacological significance of this diversity remains uncertain, it provides another potential route for differential targeting of 5-HT receptor function. Finally, there are increasing reports of allosteric modulators of 5-HT metabotropic receptors, as in recent examples for 5-HT_{2B} and 5-HT_{2C} receptors (Singh *et al.*, 2019; Wild *et al.*, 2019), and siRNA approaches for targeting 5-HT receptors have promise as noted shown for knockdown of the 5-HT_{1A} receptor (Bortolozzi *et al.*, 2012). Although the latter fields are currently in their infancy, they may provide further avenues for 5-HT drug discovery.

2.3. Ionotropic 5-HT receptor signalling

As a complement to the slow signalling elicited by metabotropic 5-HT receptors, the ionotropic 5-HT₃ receptor mediates rapid, excitatory synaptic transmission. 5-HT₃ receptors belong to the Cys-loop family of ligand-gated ion channels, which also includes nicotinic acetylcholine receptors and GABA_A receptors. They are composed of five subunits (5-HT_{3A-E}) surrounding a central ion-conducting pore that is permeable to sodium, potassium, and calcium ions (Barnes *et al.*, 2009). All 5-HT₃ receptor subunits are expressed in the CNS and, while there is uncertainty regarding the composition of the native 5-HT₃ receptor(s) in the brain, pentameric co-assemblies of 5-HT_{3A} and 5-HT_{3B} subunits is a common occurrence (for reviews see (Niesler, 2011; Thompson & Lummis, 2013). Heteromeric assemblies of 5-HT_{3AB} receptors differ in single channel conductance, calcium permeability, 5-HT concentration-response curves (potency and degree of cooperativity),

desensitization rate, current-voltage relationships, and also sensitivity to certain agents including general anaesthetics (Thompson & Lummis, 2013). To date, inclusion of the 5-HT_{3A} subunit appears to be a requisite for 5-HT₃ receptor function.

A number of high affinity 5-HT₃ receptor agonists have been identified, with meta-chlorophenylbiguanide being one of the most selective and potent, and there are many selective, high affinity competitive and non-competitive antagonists (Fakhfouri *et al.*, 2019). Allosteric modulators of the 5-HT₃ receptor and action via the pharmacological mechanism coined 'cryptic orthosteric modulation', are emerging as a new pharmacological phenomenon to add to the possibilities for 5-HT₃ receptor manipulation for therapeutic benefit (e.g. (Trattnig *et al.*, 2012; Newman *et al.*, 2013; Powell *et al.*, 2016).

Because of the restricted distribution of 5-HT₃ receptors in the CNS, fast synaptic transmission is commonly assumed to be a property of only a minority of 5-HT synapses, with transmission at the majority of 5-HT synapses being slow and neuromodulatory. However, in an exciting development it has been discovered that across species, up to 70-80% of 5-HT neurons co-localise the vesicular glutamate transporter VGLUT3 (Gras *et al.*, 2002; Hioki *et al.*, 2010; Vigneault *et al.*, 2015), implying co-release of 5-HT and glutamate from 5-HT neuron terminals via a mechanism that is currently uncertain (Figure 2). Interestingly, combined neurophysiological and optogenetic analysis of the synaptic effects of optically activated 5-HT neurons has revealed the presence of both fast, glutamate-mediated ionotropic responses and slow 5-HT-mediated metabotropic responses, often co-existing on the same postsynaptic neuron (Liu *et al.*, 2014; Kapoor *et al.*, 2016; Sengupta *et al.*, 2017). Although not yet tested, these observations raise the intriguing possibility that co-released glutamate plays a role in the therapeutic effect of 5-HT targeted drugs such as SSRIs. For example, it has been speculated that delayed onset of antidepressant action of SSRI treatment could be explained by an initial autoreceptor-mediated decrease in the glutamate component of the dual 5-HT-glutamate signalling (Fischer *et al.*, 2014).

3. Expression pattern of 5-HT receptors in the brain

A combination of approaches including receptor autoradiography, *in situ* hybridisation and immunocytochemistry has revealed the distribution of 5-HT receptors binding sites and mRNA expression in the brain (Mengod *et al.*, 2006; Mengod *et al.*, 2010; Palacios, 2016). To add to these approaches, the anatomical and cellular detail of 5-HT receptor mapping is now advancing through the generation of transgenic mice engineered to express a fluorescent or coloured reporter genes under the control of specific 5-HT receptor promoters, for instance as in the case of 5-HT_{2A} receptor (Weber & Andrade, 2010). Collectively, evidence suggests that the pattern of 5-HT receptor distribution is largely similar across vertebrate species. However, notable exceptions to this rule include the 5-HT_{1e} receptor not being expressed in rodents, the full length 5-HT_{5b} receptor not being expressed in humans, and forebrain 5-HT₃ and 5-HT₆ receptors being differentially expressed between rodents and humans.

A remarkable collection of brain atlases is currently under construction that are aiming to map the expression of a multitude of neurotransmitter receptor genes (and multiple other key genes) in the adult as well as developing mouse brain, with comparative atlases for the non-human primate and human brain (<https://portal.brain-map.org>). Presently, the mouse atlas provides a comprehensive map of the gene expression pattern of the majority of 5-HT receptors as well as the 5-HT transporter. Aside from these gene expression atlases, a high-resolution PET atlas of the binding sites for four 5-HT receptors (5-HT_{1A}, 5-HT_{1B}, 5-HT_{2A}, 5-HT₄ receptors) as well as the 5-HT transporter was recently described for the human brain (Beliveau *et al.*, 2017).

It is clear from mapping studies such as those noted above, that each 5-HT receptor subtype has a unique distribution pattern in the brain although one that often overlaps with that of other 5-HT receptor subtypes. These differential distribution patterns suggest that different 5-HT receptor subtypes are likely associated with distinct CNS functions amenable to manipulation using 5-HT receptor subtype selective pharmacological agents.

3.1 Presynaptic 5-HT receptors: 5-HT neuron feedback control

It is well established that two 5-HT receptors, 5-HT_{1A} and 5-HT_{1B} are expressed by 5-HT neurons and function as autoreceptors. 5-HT_{1A} receptors are located on the soma and dendrites of 5-HT neurons (Verge *et al.*, 1985; Riad *et al.*, 2000), and inhibit the firing of 5-HT neurons and decrease 5-HT release when activated (e.g. (Vandermaelen & Aghajanian, 1983; Sharp *et al.*, 1989; Adell & Artigas, 1998). On the other hand, 5-HT_{1B} receptors are expressed at the soma and then trafficked to the terminals where they exert inhibitory control over 5-HT release (Gothert & Weinheimer, 1979; Mounsey *et al.*, 1982; Engel *et al.*, 1986; Fink & Gothert, 2007).

Other 5-HT receptor types are reported to be expressed by midbrain 5-HT neurons, in particular 5-HT_{1D}, 5-HT_{1F}, 5-HT_{2B}, 5-HT_{2C} and 5-HT_{5A} (Erlander *et al.*, 1993; Bruinvels *et al.*, 1994; Bonaventure *et al.*, 1998; Belmer & Maroteaux, 2019; Okaty *et al.*, 2019) but the expression level of these receptors is relatively low with the exception of 5-HT_{2C}. However, in the latter case the receptor appears to be primarily located on raphe GABAergic interneurons and not 5-HT neurons (Sharp *et al.*, 2007). Nevertheless, feedback control of 5-HT neurons likely extends beyond 5-HT₁ autoreceptors to include 5-HT receptors located on postsynaptic neurons rather than 5-HT neurons themselves. For example, evidence supports a role for postsynaptic 5-HT_{1A}, 5-HT_{2A} and 5-HT_{2C} receptors in the inhibitory control of 5-HT neurons, whereas 5-HT₄ and 5-HT₆ receptors are excitatory in this regard (Lucas *et al.*, 2005; Sharp *et al.*, 2007; Sharp, 2010; Brouard *et al.*, 2015). Many of these feedback pathways appear to be localised on cortical pathways projecting back to the midbrain raphe nuclei (5-HT_{1A}, 5-HT_{2A}, 5-HT₄, 5-HT₆ receptors) although contributions from habenula inputs to the raphe (5-HT_{2C} receptors) are also implicated (Sharp *et al.*, 2007). In addition, there are numerous interactions between 5-HT receptors and other neurotransmitter systems, including noradrenaline (eg Done and Sharp, 1992), which modulate 5-HT neurons.

The physiological importance of these postsynaptic feedback pathways remains uncertain and awaits the development of genetic tools for their selective manipulation. These postsynaptic 5-HT feedback systems do, however, offer novel ways to pharmacologically target 5-HT neurons. An example of an important clinical area where knowledge of 5-HT feedback control might have therapeutic application is mood disorder, and specifically antidepressant augmentation for

treatment-resistant depression. There is good preclinical evidence that pharmacological blockade of presynaptic 5-HT_{1A} and 5-HT_{1B} receptors (Gartside *et al.*, 1995; Sharp *et al.*, 1997), and also postsynaptic 5-HT_{2A}, 5-HT_{2B}, 5-HT_{2C} and 5-HT₃ receptors (Boothman *et al.*, 2006; Cremers *et al.*, 2007; Diaz *et al.*, 2012; Betry *et al.*, 2015), will augment the 5-HT enhancing properties of SSRIs. Drugs with combined 5-HT receptor and 5-HT-transporter blocking actions continue to be sought after for their antidepressant potential (Millan, 2009; Artigas *et al.*, 2018), with vortioxetine having now reached the market (see later).

3.2 Postsynaptic 5-HT receptors

All 5-HT receptors, including 5-HT_{1A} and 5-HT_{1B} receptors, are located postsynaptically (ie expressed by non-5-HT neurons) with each 5-HT receptor subtype having its own distinct expression pattern. Even 5-HT receptors from the same family have different CNS distributions (eg 5-HT_{2A} versus 5-HT_{2C}, 5-HT_{1A} versus 5-HT_{1B}). Some 5-HT receptors have high levels of expression (5-HT_{1A} and 5-HT_{2A}) whereas others are much less abundant (5-HT_{1D}, 5-HT_{1E}, 5-HT_{1F}, 5-HT_{2B} and 5-HT_{5A}). At the macro-level, 5-HT receptors are widely distributed, with specific brain regions having distinct complements of 5-HT receptor subtypes: for instance cortical and limbic areas - 5-HT_{1A}, 5-HT_{2A/C}, 5-HT₃, 5-HT₄, 5-HT₆; basal ganglia - 5-HT_{1B}, 5-HT_{2A/C}, 5-HT₄, 5-HT₆; mesolimbic pathways - 5-HT_{1B}, 5-HT_{2A/C}, 5-HT₄ receptors; hypothalamus (eg. paraventricular and arcuate nuclei) - 5-HT_{2C}; suprachiasmatic nucleus - 5-HT₇; trigeminal nucleus - 5-HT_{1B/D/F}; dorsal vagal complex (encompassing the area postrema and nucleus tractus solitarius, and dorsal motor nucleus of the vagus nerve) - 5-HT₃.

3.3 Cellular localisation

The majority of data favour 5-HT receptors being principally expressed by neurons; evidence that they are expressed by non-neural cells is often conflicting with the possible exception of cells of the cerebrovasculature, especially as in the case of the 5-HT_{1B} receptor (Parsons, 1991; Riad *et al.*, 1998). In particular, the literature describing the expression of 5-HT receptor subtypes by glial cells is controversial and incomplete. As an example, mRNA of multiple 5-HT receptors subtypes, including 5-HT_{1A} and 5-HT_{2A} receptors were detected in rat cultured astrocytes, but none the

receptors tested were functionally coupled (Hirst *et al.*, 1998). Moreover, it is uncertain whether the receptor expression in cultured astrocytes parallels expression in astrocytes in the brain. Thus, in the case of the 5-HT_{1A} receptor, whilst there are reports that 5-HT_{1A} receptor-like immunoreactivity is present in both neurons and a large proportion of CNS astrocytes (Whitaker-Azmitia *et al.*, 1993), other groups have shown that immunoreactivity is restricted to neurons, except in the spinal cord where weak staining may correspond to astrocytes/glia cells (Gerard *et al.*, 1994; Kia *et al.*, 1996). Similarly, immunocytochemical studies demonstrate that the 5-HT_{2A} receptor is predominantly expressed in neurons but not glial cells (Morilak *et al.*, 1993). An interesting possibility is that the pattern of non-neuronal expression of 5-HT receptors is different in the developing brain, or changes in response to pathology but currently there are little data addressing these points.

Typically there is a very good match between the distribution of 5-HT receptor mRNA and protein (Mengod *et al.*, 2010), suggesting that most 5-HT receptors are not trafficked along the axon but reside preferentially at the level of the soma and dendrites. Notable exceptions are 5-HT_{1B} and 5-HT₃ receptors which are trafficked along axons to nerve terminals to modulate neurotransmitter release, and this may also be the case for 5-HT_{2A} receptors (Lamb & Aghajanian, 2006).

Given the differential expression patterns of the 5-HT receptors, all fourteen 5-HT receptor subtypes are not likely expressed by a single neuron. Rather, evidence from double- and triple-labelling *in situ* hybridisation studies support the idea that a single postsynaptic synapse may express a limited combination of perhaps 2-3 different 5-HT receptor subtypes (Mengod *et al.*, 2010). This idea is in keeping with findings from recent studies combining whole-cell patch clamp recordings with single cell transcriptome profiling. For example, analysis of the 5-HT receptor mRNA content of neurons of the bed nucleus of the stria terminalis revealed that individual neurons could be subdivided according to the prominent expression of 2-3 distinct 5-HT receptor transcripts in largely excitatory/inhibitory combinations (eg. 5-HT_{1A}/5-HT₇, 5-HT₃/5-HT₇, 5-HT_{1B}/5-HT₄, 5-HT_{1A}/5-HT_{1B}/5-HT_{2A}, and 5-HT_{1A}/5-HT_{2A} receptors) that matched electrophysiological observations (Hazra *et al.*, 2012). A similar analysis of the 5-HT receptor mRNA in the preoptic

nucleus revealed two types of neurons that predominantly expressed a combination of inhibitory (5-HT_{1A}) and excitatory (5-HT_{2C}, 5-HT₄, 5-HT₇) 5-HT receptors whereas others expressed excitatory 5-HT receptors alone, again in keeping with electrophysiological findings (Sangare *et al.*, 2016). This evidence of 5-HT receptor expression conferring both excitatory and inhibitory signalling effects of 5-HT at the single cell level is born out more generally in electrophysiological experiments recording the effects of either bath application of 5-HT or electrical and optogenetic activation of 5-HT neurons (Andrade, 2006; Andrade & Beck, 2010; Sengupta *et al.*, 2017).

It is clear that expression of specific 5-HT receptors is not restricted to a particular neuron type. For example, within the cerebral cortex, hippocampus and amygdala, 5-HT_{1A} and 5-HT_{2A} receptors are expressed both on pyramidal neurons (glutamatergic) as well as major classes of inhibitory (GABAergic) interneurons (in particular those expressing parvalbumin). Whilst cortical 5-HT₃ receptors mark a specific population of GABA interneurons with distinct chemical, morphological and anatomical properties (Lee *et al.*, 2010), these receptors are also expressed by pyramidal neurons, particularly in humans (Brady *et al.*, 2007). Contrary to early evidence from immunocytochemistry studies that 5-HT₆ receptors were located specifically on cortical GABA interneurons, more recent *in situ* hybridization findings using 5-HT₆ selective probes demonstrate that the receptor is preferentially expressed by pyramidal cells in cerebral cortex, although expression in a small population of interneurons was detected (Helboe *et al.*, 2015).

As an example of the complexity of the neuronal interactions of 5-HT, Figure 3 illustrates the present understanding of the distribution of 5-HT receptor subtypes within the microcircuitry of the basolateral nucleus in the amygdala, a key neural substrate of emotional learning (Bocchio *et al.*, 2016). Quite how this arrangement of multiple 5-HT receptor subtypes distributed across many cells types plays out at a neural network level is unknown. In this regard, it is important to consider the localization of specific 5-HT receptor subtypes on defined neuron types. Thus, a 5-HT receptor leading to membrane depolarization will have a different effect on network depending on whether it is located on an excitatory pyramidal neuron or an inhibitory interneuron. It is speculated that in the amygdala 5-HT may play an important role in the recruitment (5-HT_{2A} receptor-mediated) of

parvalbumin positive interneurons that are thought to synchronize large numbers of pyramidal neurons, and through this shape neural network synchrony and potentially facilitate fear learning (Bocchio *et al.*, 2016).

It is noteworthy that at the ultrastructural level, electron microscopy studies show that all metabotropic 5-HT receptors visualised thus far are located extrasynaptically, which has reinforced the idea that 5-HT signals via volume transmission (Descarries *et al.*, 2006). However, synaptic localisation of 5-HT receptors cannot be excluded as these are challenging studies which are often limited by the properties and specificity of available antibodies. Moreover, it is beyond doubt that 5-HT is present in vesicles that are synaptic as well as non-synaptic. As noted above, an additional complexity in signalling at 5-HT synapses is co-transmission, specifically involving ionotropic receptor signaling via co-released glutamate emerging (Sengupta *et al.*, 2017).

Looking forward, important insights into how 5-HT influences cerebral microcircuits are likely to come from the application of 5-HT-targeted optogenetic, chemogenetic and cell-specific knockout/knock-in strategies, large scale recordings of 5-HT-sensitive neural networks, as well as the development of computational modelling of 5-HT interactions with cortical microcircuitry that has already commenced (Joshi *et al.*, 2020). Recent transgenic mouse studies demonstrating that behavioural responses of SSRI treatment are dependent on the expression of specific 5-HT receptors (5-HT_{1A}, 5-HT_{1B}, 5-HT_{2A}, 5-HT_{5A}) by specific populations of hippocampal interneurons (parvalbumin and CCK) and pyramidal cells, provide examples of the power of such approaches (Samuels *et al.*, 2015; Medrihan *et al.*, 2017; Sagi *et al.*, 2019) and emphasise the importance of neuron type-specific pharmacological targeting. Neuronal network dysfunction is increasingly recognized as a symptom neuropsychiatric disorder and may provide new entry points for intervention. Once these complex interactions of 5-HT are better understood at the defined neural microcircuit level, then a more rational basis for CNS 5-HT drug discovery in the neuropsychiatric disorder field is likely to follow.

4. Effects of 5-HT receptors on behaviour and cognition: towards new drug therapies

The availability of selective pharmacological and genetic tools to manipulate 5-HT receptors, combined with a knowledge of the signalling properties of these receptors and their brain distribution, has helped establish a comprehensive knowledge of the behavioural and cognitive effects of 5-HT receptor manipulation (summarized in Table 3). This then has provided the rationale for the discovery and development of 5-HT ligands aimed at various neuropsychiatric disorders ranging from migraine and eating disorder through to depression and schizophrenia. Some of these agents have reached experimental medicine studies and clinical trials, and some have progressed all the way to therapeutic application. This subject is addressed in detail in a recent publication (Barnes et al, 2020), but salient points are covered below.

4.1 5-HT₁ receptor family

5-HT_{1A} receptors: Across a range of species, 5-HT_{1A} receptor agonists evoke a range of behavioural and physiological effects including altered motor function (especially aspects of the 5-HT behavioural syndrome), body temperature, and neuroendocrine activity. Moreover, there is an abundance of preclinical and clinical evidence that 5-HT_{1A} receptor agonists have antidepressant and anxiolytic properties, and influence a range of cognitive domains relevant to symptoms of schizophrenia (for review see (Traber & Glaser, 1987; Handley, 1995; Newman-Tancredi, 2010). The many and diverse behavioural effects of 5-HT_{1A} receptor agonists are likely to reflect an action at 5-HT_{1A} receptors in multiple forebrain and midbrain sites; for example, 5-HT_{1A} autoreceptor activation has been linked to anxiolytic effects whereas activation of postsynaptic 5-HT_{1A} receptors is associated with antidepressant effects (see (Richardson-Jones *et al.*, 2010; Richardson-Jones *et al.*, 2011; McCreary & Newman-Tancredi, 2015; Samuels *et al.*, 2016).

In support of this differential impact of pre- versus postsynaptic 5-HT_{1A} receptors on anxiety and depression mechanisms, it is reported that mice with knockdown of the presynaptic 5-HT_{1A} autoreceptor have a high anxiety phenotype whereas mice with knockdown of the postsynaptic 5-HT_{1A} receptor have a depressive-like phenotype (Richardson-Jones *et al.*, 2011). Interestingly these phenotypes are recapitulated by 5-HT_{1A} receptor suppression during a critical period in early

life and not blockade of 5-HT_{1A} receptors in adult mice (Richardson-Jones *et al.*, 2011; Garcia-Garcia *et al.*, 2014; Garcia-Garcia *et al.*, 2016). This suggests that the phenotypes are developmental in origin; that is loss of pre- or postsynaptic 5-HT_{1A} receptor function during early life disrupts neural circuit formation leading to altered anxiety/depression behaviour in adulthood. A similar picture has emerged regarding the high anxiety phenotype of 5-HT transporter mutant mice (Ansorge *et al.*, 2004; Rebello *et al.*, 2014). Consideration of developmental mechanisms is clearly important when interpreting the behavioural phenotype of genetically engineered mice with altered 5-HT receptor expression, as noted previously (Gingrich *et al.*, 2003; Berger & Tecott, 2006; O'Leary & Cryan, 2010).

This functional importance of 5-HT_{1A} receptors has generated much research into the therapeutic potential of 5-HT_{1A} receptor ligands. In particular, in the 1990's the 5-HT_{1A} agonist buspirone was approved for the clinical use as an anxiolytic agent, and the structurally related azapirones gepirone and tandospirone, demonstrated efficacy as antidepressant agents in clinical trials. The targeting of 5-HT_{1A} autoreceptors to speed up and augment antidepressant action generated considerable interest, and antidepressant augmentation was detected in clinical trials with the 5-HT_{1A}/β-adrenoceptor ligand pindolol (Whale *et al.*, 2010) although not the novel 5-HT_{1A} receptor antagonist DU-125530 (Scorza *et al.*, 2012). Moreover, the latter concept triggered the development of the novel antidepressants vilazodone (Dawson & Watson, 2009) and vortioxetine (Sanchez *et al.*, 2015), which have combined high affinity for the 5-HT uptake transporter and 5-HT_{1A} receptor (and multiple other 5-HT receptors in the case of vortioxetine - see later). Whereas additional studies are required to confirm that vilazodone has safety and efficacy over and above SSRI and other antidepressant alternatives (Stuivenga *et al.*, 2019), vortioxetine continues to show promise as a valid option for depressed patients who have not been effectively treated with first-line pharmacotherapies (Thase *et al.*, 2017).

The recent findings of canonical and non-canonical signalling properties of the 5-HT_{1A} receptor noted above, raise the possibility of developing biased 5-HT_{1A} receptor agonists to evoke a restricted range of selected behavioural effects. Indeed, a number of such agents are in

development for a range of CNS disorders. For example, NLX-112 (formerly named F13640) is considered a potential treatment of Parkinson's disease patients suffering from L-DOPA-induced dyskinesia (Newman-Tancredi *et al.*, 2018). NLX-112 is a 'full' agonist but shows preferential activation of ERK signaling, and activates 5-HT_{1A} autoreceptors to inhibit 5-HT cell firing. Here the thinking is that the unwanted motor effects of L-DOPA are mediated by the ectopic synthesis and release of dopamine from 5-HT neurons, and that the symptoms can be ameliorated by inhibition of 5-HT neuronal activity (Fisher *et al.*, 2020). Another biased 5-HT_{1A} receptor agonist NLX-101 (F15599), is reported to preferentially activate postsynaptic 5-HT_{1A} receptors and show antidepressant, pro-cognitive and neuroprotective properties in animal models (Becker *et al.*, 2016; Sniecikowska *et al.*, 2019; Vidal *et al.*, 2019; Aguiar *et al.*, 2020).

5-HT_{1B} receptors. Both preclinical and clinical studies, emphasise a role for 5-HT_{1B} ligands in the management of depression and anxiety (see (Ruf & Bhagwagar, 2009; Fakhoury, 2016) as well as aggression and impulse control (see (Nautiyal *et al.*, 2015). Moreover, the role of pre- versus postsynaptic 5-HT_{1B} receptors in these behaviours is being addressed utilising tissue-specific and time-dependent conditional 5-HT_{1B} receptor mutant mice. A number of selective 5-HT_{1B} receptor antagonists are available including SB224289 (Gaster *et al.*, 1998), however, progression with this receptor has been hampered to some extent by the lack of 5-HT_{1B} receptor agonists with sufficient selectivity or brain penetration.

Evidence suggests that 5-HT_{1B} receptor antagonists are anxiolytic and antidepressant in animal models (Fakhoury, 2016), which is consistent with reports that mice with a global 5-HT_{1B} receptor knockout have an anxiolytic and antidepressant-like phenotype (Mayorga *et al.*, 2001; Jones & Lucki, 2005; Bechtholt *et al.*, 2008). Interestingly, it was reported recently that the latter phenotype is recapitulated in genetic mice with loss of 5-HT_{1B} autoreceptors but not those with loss of postsynaptic 5-HT_{1B} receptors (Nautiyal *et al.*, 2016). Moreover, this phenotype was recapitulated by knockout of 5-HT_{1B} autoreceptors in adulthood and not during early postnatal life, making it unlikely that a developmental mechanism is involved (Nautiyal *et al.*, 2016). Collectively, these data suggest that drugs that selectively block 5-HT_{1B} autoreceptors may be useful for the treatment

of anxiety and depression. Currently there are no drugs with this property although developments with selective 5-HT_{1A} autoreceptor ligands (see above) offer the prospect for similar agents targeting 5-HT_{1B} autoreceptors.

Another interesting effect of global 5-HT_{1B} receptor knockout is increased aggression and impulsivity, which is in keeping with earlier reports that certain 5-HT_{1B} receptor agonists ('serenics') have anti-aggressive properties (Olivier *et al.*, 1995). The recently available conditional 5-HT_{1B} receptor knockout mice has allowed further examination of the role of pre- versus postsynaptic 5-HT_{1B} receptors in aggression and impulsivity. Interestingly, recent studies using the conditional 5-HT_{1B} receptor knockout mice found that heightened aggression and impulsivity was linked to loss postsynaptic 5-HT_{1B} receptors and not 5-HT_{1B} autoreceptors (Nautiyal *et al.*, 2015). Furthermore, it was observed that the impulsivity phenotype did not involve a developmental mechanism (i.e. it was not recapitulated by early life knockout), although the elevated aggression phenotype did have early life origins. These data raise the interesting possibility that drugs which selectively target the postsynaptic versus presynaptic 5-HT_{1B} receptors may be therapeutically effective in the control of heightened impulsivity.

5-HT_{1D/e/F} receptors. As yet no behavioural response can be confidently ascribed to activation of 5-HT_{1D}, 5-HT_{1E} or 5-HT_{1F} receptors. Progress in this regard has been limited by the lack of drug tools with sufficient selectivity or brain penetration, and also doubts regarding the functional importance of these receptors given their low levels of expression. However, the 5-HT_{1D} receptor antagonist BRL15572 (Price *et al.*, 1997) has been important since in combination with the 5-HT_{1B} receptor antagonist SB224289, it allows the discrimination of 5-HT_{1B} or 5-HT_{1D} receptor-mediated responses. Nevertheless, the significance of these receptors to neuropharmacology ought not be underestimated in the sense that triptans (5-HT_{1B/D} receptor agonists) are currently considered the gold standard for acute treatment of migraine (with the relative importance of 5-HT_{1B} versus 5-HT_{1D} remaining uncertain). Although triptans are not efficacious in all patients, and are contraindicated in certain patient groups (eg. coronary artery disease), 5-HT_{1F} receptor agonists are emerging as a potential migraine treatment alternative. In particular, the selective 5-HT_{1F} receptor agonist

lasmiditan (also known as COL-144 and LY573144; (Nelson *et al.*, 2010), which lacks the vasoconstriction property of triptans, is effective in phase 3 clinical trials (Goadsby *et al.*, 2019), and it's global general release as an antimigraine agent looks imminent. Although the mechanism of lasmiditan is not yet established the drug is brain penetrant and involvement of central 5-HT_{1F} receptors seems a likely (potentially via inhibition of the trigeminocervical complex).

4.2 5-HT₂ receptor family

The behavioural effects of 5-HT₂ receptor agonists in rodents are many, ranging from changes in both unconditioned (e.g. head-twitches, increased motor activity, hypophagia, hyperthermia) and conditioned responses (e.g. punished responding, drug discrimination), as reviewed previously (Koek *et al.*, 1992; Barnes & Sharp, 1999; Halberstadt, 2015). It has become possible to identify the role of the different 5-HT₂ receptor subtypes in these behaviours with some degree of confidence, through the availability of highly selective antagonists (for each of 5-HT_{2A}, 5-HT_{2B} and 5-HT_{2C} receptors) and agonists (especially 5-HT_{2C}) as well as mutant mice with the different receptors selectively knocked out (Heisler *et al.*, 2007b; Halberstadt, 2015; Di Giovanni & De Deurwaerdere, 2016).

5-HT_{2A} receptors: There is strong evidence from the use of selective pharmacological and genetic tools that the 5-HT_{2A} receptor is a major contributor to multiple functional responses in animals including 5-HT agonist induced head-twitches, drug discrimination cues, hyperthermia and changes in exploratory behaviour (Halberstadt, 2015). Furthermore, much evidence suggests that the 5-HT_{2A} receptor is the mediator of the hallucinogenic effects of psychedelic drugs in humans. For example, 5-HT_{2A} receptor agonist-induced head-twitches have strong predictive value in this regard (Halberstadt *et al.*, 2020). Despite its simplicity, the 5-HT_{2A} receptor agonist-induced head-twitch response is well characterized using both pharmacological and genetic approaches; the response is likely mediated via the phosphoinositide signaling pathway, and arises from 5-HT_{2A} receptor activation in the forebrain and the prefrontal cortex in particular (Gonzalez-Maesó *et al.*, 2007; Halberstadt, 2015; Antoniadou *et al.*, 2018).

In the 1960's psychedelic drugs like LSD and psilocybin were widely used by psychotherapists as an aid to treat depression as well as anxiety-related disorders and addictions, and results were generally encouraging. In the last few years there has been renewed interest in the use of these agents for therapeutic purposes. Psilocybin in particular has been subject to investigation in a range of human psychopharmacological and brain imaging studies, which have contributed proof-of-principle and dose/safety data for clinical trials (Nutt, 2016; Nutt *et al.*, 2020). Recent clinical data demonstrate that a single dose of psilocybin (combined with psychological support) causes a sustained lowering of depression and anxiety ratings in cancer patients (Griffiths *et al.*, 2016; Ross *et al.*, 2016; Goldberg *et al.*, 2020) and treatment resistant-depression (Carhart-Harris *et al.*, 2016). Moreover, a recent PET study in human volunteers using the novel 5-HT_{2A} agonist radioligand [¹¹C]-Cimbi-36 found that psychotropic effects of psilocybin was closely associated with 5-HT_{2A} receptor occupancy (Madsen *et al.*, 2019), emphasizing the importance of this receptor in the psychotropic effects of psilocybin. Evidence that hallucinogenic 5-HT_{2A} receptor agonists alter markers of synaptic plasticity in animals provides a rational molecular/cellular account of the antidepressant effect of these agents (Vollenweider & Kometer, 2010).

The potent 5-HT_{2A} receptor antagonist properties of antipsychotics typified by clozapine has been linked to an advantageous side effect profile and improved efficacy (Meltzer & Massey, 2011). Moreover, high affinity for the 5-HT_{2A} receptor is feature of the newer antipsychotics such as aripiprazole and brexpiprazole, although high affinity for the 5-HT_{1A} receptor (and other receptors) may play an important role in their actions (McCreary & Newman-Tancredi, 2015). This said, whilst recent meta-analyses suggest that antipsychotics vary in their efficacy and adverse effects (Huhn *et al.*, 2019), currently there is no simple pharmacological account of the individual differences. Certainly, 5-HT_{2A} receptor blockade is unlikely to be sufficient by itself to generate a useful antipsychotic effect due to the lack of antipsychotic effect of the selective 5-HT_{2A} receptor antagonist, MDL 100,907 (volinaserin; (de Paulis, 2001). However, recent evidence that the 5-HT_{2A} receptor inverse agonist pimavanserin has antipsychotic actions in relevant animal models (Vanover *et al.*, 2006) and in certain patient populations (Fox, 2014), emphasizes the value of 5-HT_{2A} receptor modulation in the treatment of psychosis. In this regard, the interesting interaction

between 5-HT_{2A} receptors and mGlu2 glutamate receptors is noteworthy as this offers interesting avenues for the future development of drugs with combined 5-HT_{2A} receptor antagonist - mGlu2 agonist properties (Shah & Gonzalez-Maeso, 2019).

Recent reports that 5-HT_{2A} receptor antagonists augment the effect of 5-HT uptake inhibitors in preclinical models (Marek *et al.*, 2003; Marek *et al.*, 2005; Boothman *et al.*, 2006), may be associated with evidence that drugs with 5-HT_{2A} receptor antagonist properties are helpful as augmenting agents in treatment resistant depression (Marek *et al.*, 2003). Although the mechanism behind this effect of 5-HT_{2A} receptor blockade is not certain, it may link to evidence of an inhibitory 5-HT_{2A} receptor-mediated feedback on 5-HT neurons (Sharp *et al.*, 2007).

Interestingly, the 5-HT_{2A} receptor has also been associated with impulse control; thus, selective 5-HT_{2A} receptor antagonists consistently decrease impulsivity in animal models (Winstanley *et al.*, 2004; Winstanley, 2011; Barkus *et al.*, 2018) and this is supported by psychopharmacological studies in humans using the non-selective 5-HT_{2A} receptor antagonist quetiapine (Rock *et al.*, 2013). In this regard it is noteworthy that lithium and the repurposed lithium-mimetic ebselen are both reported to attenuate 5-HT_{2A} receptor function, likely via inhibition of the phosphoinositide pathway (Singh *et al.*, 2013; Antoniadou *et al.*, 2018). Moreover, ebselen reduced impulsivity in animal as well as human paradigms (Masaki *et al.*, 2016; Barkus *et al.*, 2018). This raises the possibility that 5-HT_{2A} receptor antagonists/inverse agonists as well as novel lithium-like agents such as ebselen may have utility in the control of disorders of impulse control (see also following section on 5-HT_{2C} receptors).

5-HT_{2B} receptors: Evidence of relatively low 5-HT_{2B} receptor expression in the brain and the lack of selective 5-HT_{2B} receptor ligands has hampered progress in establishing the CNS function of these receptors. Interestingly, 5-HT_{2B} knockout mice have striking phenotypes including deficits in sensorimotor gating, social interaction, attention, learning and memory, as well as elevated impulsivity and altered sleep patterns, some of which (sleep, sensorimotor gating) can be phenocopied by 5-HT_{2B} receptor blockade using the selective 5-HT_{2B} receptor antagonist

RS127445 (Pitychoutis *et al.*, 2015). However, 5-HT_{2B} knockout is also associated with severe cardiac abnormalities and embryonic and postnatal lethality, which might lead to neurodevelopment issues in surviving animals that could confound the interpretation of these adult CNS phenotypes (as noted above). Although studies involving conditional 5-HT_{2B} knockout strategies and further pharmacological phenocopying are awaited, these data raise interesting possibilities regarding the functional role of CNS 5-HT_{2B} receptors. Recently discovered interactions between 5-HT_{2B} receptors and raphe 5-HT neurons (Belmer & Maroteaux, 2019) as well as the dopamine system (Devroye *et al.*, 2018), emphasizing a possible role of these receptors in the treatment of depression, are noteworthy in this regard.

5-HT_{2B} receptor agonism in the periphery is associated with unwanted and potentially harmful adverse effects including pulmonary hypertension, and a number of therapeutic agents with 5-HT_{2B} receptor agonist properties (eg. fenfluramine, pergolide, cabergoline) have been withdrawn (Hutcheson *et al.*, 2011). Nevertheless, recent data showing biased agonism at the 5-HT_{2B} receptor (Wacker *et al.*, 2013) offers the prospect of future 5-HT_{2B} receptor agonists devoid of these systemic adverse effects.

5-HT_{2C} receptors: Early neuropharmacological studies using non-selective agents associated 5-HT_{2C} receptor activation with various behavioural and physiological effects in rodents such as hypolocomotion, hypophagia, anxiety, penile erection and hyperthermia, as reviewed earlier (Barnes & Sharp, 1999). With the introduction of more selective 5-HT_{2C} receptor agonists (eg. CP-809101, lorcaserin) and antagonists (eg. SB242084) and 5-HT_{2C} knock out mice, the list 5-HT_{2C} receptor functions has expanded to include compulsive drug- and food-seeking, central control of energy homeostasis, oral dyskinesia, wakefulness and control seizure threshold (Di Giovanni & De Deurwaerdere, 2016).

The link between 5-HT_{2C} receptors and addictive behaviours associated with food and psychostimulant drugs has been under intense investigation (Higgins & Fletcher, 2015; Howell & Cunningham, 2015). It is clear from rodent studies that 5-HT_{2C} receptor activation reduce palatable

food consumption and metabolism, likely via an action on hypothalamic nuclei that promote satiety and regulate energy balance pathways (Heisler *et al.*, 2006; Heisler *et al.*, 2007a; Lam *et al.*, 2008). These agents also disrupt dopamine-mediated addiction mechanisms that lead up to compulsive drug use such as the positive reinforcement, behavioural sensitization, and reinstatement properties of psychostimulants. Interestingly, separate studies have revealed a link between 5-HT_{2C} receptors and impulse control; thus 5-HT_{2C} receptor agonists have been found to reduce premature responding whereas 5-HT_{2C} receptor antagonists have the opposite effect (Higgins *et al.*, 2003; Winstanley *et al.*, 2004; Fletcher *et al.*, 2007; Higgins *et al.*, 2016). Given that impulsivity may influence many aspects of compulsive drug- and food-seeking behaviour, it is speculated that 5-HT_{2C} receptors may modulate addiction indirectly via its effects on impulsive behavior (Higgins *et al.*, 2017).

As a consequence of these discoveries in preclinical studies, the selective 5-HT_{2C} receptor agonist lorcaserin advanced into clinical trial and has been approved for the treatment of obesity (when combined with lifestyle modification). Although the overall effect size of lorcaserin appears to be modest, individual variation in response indicates that patient stratification could be used to optimize treatment outcome in the future (Higgins *et al.*, 2020). These clinical studies in obesity combined with accumulating evidence that lorcaserin is safe and tolerated by patients, may pave the way for further studies into the therapeutic potential of lorcaserin in other clinical indications.

Earlier studies reported opposing functional interactions between 5-HT_{2C} and 5-HT_{2A} receptors (Berendsen & Broekkamp, 1990), and more recent data are in keeping with this. For example, both 5-HT_{2A} receptor antagonists and 5-HT_{2C} receptor agonists lower impulsivity in rodent models (Winstanley, 2011). This interaction could explain why non-selective 5-HT_{2A/2C} receptor ligands and even 5-HT augmenting agents such as SSRIs have generally poor efficacy in drug addiction models, where impulsivity mechanisms have recognised importance. Consequently, it has been proposed that an optimal way to control addictive behaviour may be a 5-HT drug that combines in the same molecule, agonist activity at the 5-HT_{2C} receptor and antagonist activity at the 5-HT_{2A} receptor (Anastasio *et al.*, 2015; Higgins & Fletcher, 2015). Additional approaches for future

investigation could include 5-HT_{2C} receptor agonists with biased agonist properties or positive allosteric modulators of the 5-HT_{2C} receptor.

4.3 5-HT₃ receptors

Outside of the well-established role of 5-HT₃ receptors in the control of emesis (likely central as well as peripheral mechanism), 5-HT₃ receptors have been linked to multiple behavioural effects, ranging from changes in anxiety and cognition to altered pain processing and sensitivity to addictive drugs. Most of the early evidence for this comes from studies of the behavioural effects of 5-HT₃ receptor ligands (mostly antagonists) in animal models; these and more recent findings are extensively reviewed elsewhere (Costall & Naylor, 1992; Bentley & Barnes, 1995; Barnes & Sharp, 1999; Walstab *et al.*, 2010; Gupta *et al.*, 2016). However, many of the behavioural effects of selective 5-HT₃ receptor antagonists observed in preclinical investigations are not confirmed by studies of these agents in clinical populations (Bentley & Barnes, 1995; Walstab *et al.*, 2010).

The apparent failure for the translation of these preclinical findings could in part be explained by sub-optimal clinical dosing, since a bell-shaped dose-response curves are often observed for 5-HT₃ receptor antagonists, particularly in relation to CNS effects. Furthermore the differential expression of forebrain 5-HT₃ receptors when comparing species (e.g. rat versus human; see (Parker *et al.*, 1996) may underlie some species differences in the behavioural consequences following 5-HT₃ receptor antagonism. Nevertheless, the involvement of 5-HT₃ receptors in some of these behaviours receives support from more recent studies of mutant mice with altered 5-HT_{3A} receptor expression.

In particular, support for a role for 5-HT₃ receptors in depression/anxiety-related behaviours, learning and memory, and pain processing comes from the phenotypic analysis of transgenic mice with 5-HT_{3A} receptor knockout or overexpression (Harrell & Allan, 2003; Kelley *et al.*, 2003; Berger & Tecott, 2006). Interpretation of the phenotypes of these mice is complicated by findings that, i) they are not always phenocopied by pharmacological agents, ii) they are dependent on the mouse background strain, and iii) over-expression and deletion of the 5-HT_{3A} receptor sometimes

produce similar effects (for review see (Berger & Tecott, 2006; O'Leary & Cryan, 2010). However, in the case of a putative anxiolytic effect of 5-HT₃ receptor blockade, it is noteworthy that the 5-HT₃ receptor antagonist alosetron was reported to reduce emotional responding in patients with irritable bowel syndrome (Mayer *et al.*, 2002). This effect was associated with reduced activity in limbic regions including amygdala as measured by PET imaging, suggesting a potential anxiolytic mechanism. This said peripheral mechanisms may have contributed, including effects of 5-HT₃ receptor antagonism on enteric neurons (Mayer *et al.*, 2002).

More recent evidence associating 5-HT₃ receptors with emotional behaviours and cognition comes from findings with vortioxetine (see also above), which has atypical pharmacology at the 5-HT₃ receptor with initial agonist action followed by long-term unsurmountable receptor inhibition (Ladefoged *et al.*, 2018) combined with affinity for 5-HT_{1A}, 5-HT_{1B}, 5-HT_{1D}, 5-HT₇ and 5-HT transporter binding sites. Vortioxetine has significant antidepressant and pro-cognitive activity in both rodent models and clinical trials (Mork *et al.*, 2012; Sanchez *et al.*, 2015) and is currently marketed as an antidepressant with cognition enhancing properties. In spite of vortioxetine's polymodal pharmacology, blockade of 5-HT₃ receptors is thought to play a prominent role in its mechanism of action, particularly in relation to cognition. Thus, in rodents vortioxetine preferentially occupies 5-HT₃ receptors and the 5-HT transporter at low doses, and 5-HT₃ receptor blockade alone can produce cognition-enhancing effects similar to vortioxetine (Mork *et al.*, 2012; Sanchez *et al.*, 2015). A current mechanistic explanation of these findings is that blockade of 5-HT₃ receptors on specific populations of cortical GABA interneurons contributes to vortioxetine's action (Riga *et al.*, 2016).

4.4 5-HT₄ receptors

Earlier preclinical studies detected cognition-enhancing as well as anxiolytic effects of 5-HT₄ receptor agonists as reviewed previously (Barnes & Sharp, 1999), and these observations have proved consistent in later work (Bockaert *et al.*, 2011; Claeysen *et al.*, 2015; Hagena & Manahan-Vaughan, 2016). Stemming in part from studies of 5-HT₄ knockout mice (Compan *et al.*, 2004), a role of 5-HT₄ receptors in feeding behaviour also now seems clear, with 5-HT₄ receptor agonists

and antagonists have hypo- and hyper-phagic properties, respectively (Jean *et al.*, 2007; Bockaert *et al.*, 2011).

Pro-cognitive effects of 5-HT₄ receptor agonists (eg. RS673333, BIMU 1/BIMU 8) have been described across a range of species and in a variety of experimental paradigms that model different aspects of short- and long-term memory, many of them dependent on hippocampus where 5-HT₄ receptors are reasonably abundant (Hagena & Manahan-Vaughan, 2016). These agents also reverse the cognitive deficits induced by factors such as ageing, pharmacological interventions (e.g. muscarinic antagonists) and Alzheimer's disease-like pathology. The cellular mechanisms underlying the pro-cognitive effects of 5-HT₄ receptor agonists are not certain but may include increased release of 5-HT and acetylcholine, induction of synaptic plasticity, increased synaptic spine formation and altered hippocampal network properties (Boddeke & Kalkman, 1990; Ge & Barnes, 1996; Claeysen *et al.*, 2015; Hagena & Manahan-Vaughan, 2016). 5-HT₄ receptor agonists such as RS673333 also promote amyloid precursor protein cleavage, which has led to speculation that these agents may be useful in the management of Alzheimer's disease (Claeysen *et al.*, 2015). In this regard, it is of interest that the novel compound donecopride which has combined 5-HT₄ receptor agonist and acetylcholinesterase inhibitor properties, was recently reported to have cognition enhancing and neuroprotective properties in a mouse model of Alzheimer's disease (Rochais *et al.*, 2019).

5-HT₄ receptor agonists evoke rapid antidepressant effects in animal models (Lucas *et al.*, 2007) (Vidal *et al.*, 2014; Samuels *et al.*, 2016), and there is preclinical evidence that 5-HT₄ receptor activation plays an important role in the action of SSRIs (Mendez-David *et al.*, 2014) and may be helpful in SSRI augmentation (Licht *et al.*, 2010b). Antidepressant administration causes adaptive changes in 5-HT₄ receptor expression and function (Licht *et al.*, 2010a). Moreover, in a recent PET study using the 5-HT₄ radioligand ¹¹C-SB207145, reported that reduced striatal 5-HT₄ receptors was associated with a family history of depression (Madsen *et al.*, 2014). The mechanism involved in the antidepressant effects of 5-HT₄ receptor agonists is uncertain but a contributory factor may

be activation of a positive feedback control of midbrain 5-HT neurons via 5-HT₄ receptor located in the frontal cortex or hippocampus (Ge & Barnes, 1996; Lucas *et al.*, 2005; Licht *et al.*, 2010b).

Aside from rodent studies, there is an earlier report that the 5-HT₄ receptor agonist RS 17017 improved the cognitive performance in non-human primates (Terry *et al.*, 1998). More recently in a study of healthy human volunteers, a single dose of the 5-HT₄ receptor agonist prucalopride was found to have pro-cognitive effects in a battery of learning and memory tests, although the drug was not active in models of emotional processing that have antidepressant predictive capability (Murphy *et al.*, 2019). Although exploratory in nature, the latter study reported relatively mild adverse effects of prucalopride, in particular headache, nausea and diarrhoea, and consistent with that expected of agents with 5-HT₄ receptor agonist actions. Further studies are required to ascertain the general tolerability of 5-HT₄ receptor agonists, and the extent to which adverse effects might hamper the clinical development of these agents.

4.5 5-HT₅ receptors

Both 5-HT_{5A} and 5-HT_{5B} receptor subtypes have been detected in the CNS of multiple species, but the full length 5-HT_{5B} receptor is not expressed in humans (interruption of coding sequence by stop codons), thereby negating the usefulness of this receptor as a therapeutic target (Nelson, 2004). Due to the lack of suitably selective drug tools there is currently limited information on the CNS functions of the 5-HT_{5A} receptor. A number of drugs with 5-HT_{5A} receptor antagonist activity have been investigated in rodents for anxiolytic, antidepressant and antipsychotic activity, but to date no consistent behavioural effect of 5-HT_{5A} blockade has been identified (Kassai *et al.*, 2012), although a possible link to memory has been noted (Gonzalez *et al.*, 2013). However, these studies should be treated cautiously because they rely on the use of the 5-HT_{5A} receptor antagonist SB-699551; while this agent possesses high affinity for the human and guinea pig 5-HT_{5A} binding sites (~pKi 8.3), its affinity for these sites in the rat and mouse is 2 orders of magnitude lower (pKi 6.3; (Thomas *et al.*, 2006). It is reported that 5-HT_{5A} receptor knockout mice display increased exploratory activity without altered anxiety levels (Grailhe *et al.*, 1999). A drawback of the latter study is that in the absence of supporting data from phenocopying experiments using 5-HT_{5A}

receptor antagonists, it remains uncertain whether these behaviours are driven by the absence of 5-HT_{5A} receptor in the adult brain.

Intriguingly, in 5-HT_{5A} receptor knockout mice the locomotor activation induced by LSD was blunted, suggesting that 5-HT_{5A} receptor activation might contribute to the psychotropic effects of psychedelic agents (Grailhe *et al.*, 1999), and therefore that 5-HT_{5A} antagonists may be antipsychotic. In accordance with this latter finding, a recent study reported that in rats the LSD discriminatory cue was attenuated, albeit partially, by pretreatment with SB-699551-A (Popik *et al.*, 2019) although note the above caveat about this agent. Another recent study associated 5-HT_{5A} receptor function with antidepressant action. Specifically, using a cell-specific 5-HT_{5A} receptor knockout strategy, it was found that the activity of 5-HT_{5A} receptors in hippocampal (dentate gyrus) parvalbumin interneurons was required for behavioural effects of chronic SSRI treatment (Sagi *et al.*, 2019).

4.6 5-HT₆ receptors

The cognitive and behavioural functions of the 5-HT₆ receptor were somewhat obscure until the discovery of selective 5-HT₆ receptor ligands, although the latter development is complicated by important species differences in the pharmacological profile of the 5-HT₆ receptor which is much closer between human and rat, than human and mouse (Setola & Roth, 2003). Moreover, levels of 5-HT₆ receptor expression are also lower in mouse compared to rats and humans (Hirst *et al.*, 2003). Although earlier 5-HT₆ receptor ligands lacked selectivity and brain penetrability, these problems are largely overcome by more recently developed compounds, including the agonists WAY181187 and WAY208466 (Schechter *et al.*, 2008), and antagonists LuAE58054 (idalopirdine), SB258585, and SB399885 (Hirst *et al.*, 2003; Hirst *et al.*, 2006; Arnt *et al.*, 2010). The use of such compounds in rat behavioural models has identified a role for the receptor in a range of CNS functions and learning and memory (Mitchell & Neumaier, 2005; de Jong & Mork, 2017), as well as feeding, addiction and seizure control (Karila *et al.*, 2015; Brodsky *et al.*, 2016; Chaumont-Dubel *et al.*, 2019). In particular, there are consistent findings that 5-HT₆ receptor antagonists enhance learning and memory in preclinical models, ranging from novel object and social recognition to

spatial memory tasks (de Jong & Mork, 2017). These effects are observed in naive animals as well as in animals with memory deficits, for example induced by pharmacological means such as cholinergic antagonists.

The mechanism underlying the pro-cognitive effects of 5-HT₆ receptor blockade is uncertain. An interaction with the cholinergic system is supported by evidence that treatment with the 5-HT₆ receptor antagonist idalopirdine augments the cognition enhancing effects of an acetylcholinesterase inhibitor in both animal models and patients with Alzheimer's disease (Wilkinson *et al.*, 2014; de Jong & Mork, 2017; Kucinski *et al.*, 2017). Moreover, there is neurophysiological and neurochemical evidence that this drug combination has a synergistic effect on cholinergic function (Herrik *et al.*, 2016). However, recent data show that 5-HT₆ receptors are not expressed by cholinergic neurons (Helboe *et al.*, 2015), which would invoke an indirect mechanism. A mechanism involving increased information processing through cortico-striatal circuits was recently proposed (Kucinski *et al.*, 2017).

The evidence that 5-HT₆ receptor antagonists are cognition-enhancing led to their clinical trial in Alzheimer's disease. To date however, despite encouraging findings in early studies, large scale clinical trials with idalopirdine, have not detected a significant therapeutic effect (Atri *et al.*, 2018; Khoury *et al.*, 2018; Matsunaga *et al.*, 2019), and negative findings have also been reported for other 5-HT₆ receptor antagonists (Bennett, 2018). The explanation for the lack of translation from preclinical studies is not clear but is likely to be related to multiple factors, ranging from insufficient receptor occupancy to patient heterogeneity or simply poor predictive validity of the animal models used. Investigation into the potential utility of these compounds in the treatment of cognitive impairment associated with other disorders including schizophrenia is ongoing.

A complication in understanding the pro-cognitive effects of 5-HT₆ receptor antagonists is the paradox that 5-HT₆ receptor agonists are also reported to have pro-cognitive effects in some, albeit not all, animal models (e.g. (Schechter *et al.*, 2008; Burnham *et al.*, 2010; Kendall *et al.*, 2011; Meneses *et al.*, 2011)). Part of the explanation could lay in the cognitive domain being measured,

and to date few studies have systematically compared selective 5-HT₆ receptor agonists and antagonists in the same model. There also remains the intriguing possibility that the full answer lies in the pharmacology of 5-HT₆ receptor ligands, and that their categorization in terms of partial agonist, inverse agonist and even biased agonist is not yet complete (e.g. (Romero *et al.*, 2006). Nevertheless, 5-HT₆ receptor partial or inverse agonists are potential candidates for future trials in Alzheimer's disease and other disorders in which cognitive deficits are a feature.

4.7 5-HT₇ receptors

Analogous to the 5-HT₆ receptor, the behavioural and cognitive functions of the 5-HT₇ receptor are now beginning to be revealed through important advances in 5-HT₇ receptor pharmacology with selective agonists (AS-19, LP-211, E-55888) as well antagonists (SB-258719, SB-269970) being available, as well as a 5-HT₇ receptor knockout mouse (for review see (Blattner *et al.*, 2019). Earlier studies finding that 8-OH-DPAT was hypothermic concluded that 5-HT_{1A} receptor were involved before this drug was also recognized as a 5-HT₇ receptor agonist. It is now apparent that 5-HT₇ receptor agonists such as are hypothermic in various species, and that both 5-HT_{1A} and 5-HT₇ receptors were involved in the effect of 8-OH-DPAT (Hagan *et al.*, 2000; Brenchat *et al.*, 2012). Evidence suggests that the 5-HT₇ receptor is associated with not just temperature control but a wide variety of CNS processes including regulation of circadian rhythms, mood, learning and memory, seizure threshold and pain processing as well as mechanisms of addiction. This literature is extensively reviewed elsewhere (Hedlund, 2009; Hauser *et al.*, 2014; Blattner *et al.*, 2019), and only highlights are noted here.

Much preclinical evidence implicates the 5-HT₇ receptor in mechanisms of learning and memory. For example, 5-HT₇ receptor KO mice display specific impairments in various models of spatial learning, and also demonstrate deficits in long term potentiation (Roberts *et al.*, 2004). Moreover, selective 5-HT₇ receptor antagonists such as SB-269970 reverse cognitive deficits induced pharmacologically, in particular by NMDA antagonists (Meneses, 2004), and 5-HT₇ receptor blockade might contribute to the pro-cognitive actions of antipsychotics such as lurasidone

(Horisawa *et al.*, 2013). Evidence also supports a role for the 5-HT₇ receptor in seizure control. For instance, both antagonists SB-258719 and SB-269970 demonstrate anticonvulsant properties in rodent epilepsy models, whereas the agonist AS-19 was proconvulsant (Graf *et al.*, 2004; Yang *et al.*, 2012).

The 5-HT₇ receptor modulation of circadian rhythms was established in early studies showing that the circadian phase shift of suprachiasmatic nucleus neurons induced by the 5-HT_{1A} receptor agonist 8-OH-DPAT was mediated by 5-HT₇ and not 5-HT_{1A} receptors (Lovenberg *et al.*, 1993). On the basis of these findings, studies have explored the role of the 5-HT₇ receptor in sleep regulation. Evidence from rodent studies shows that 5-HT₇ receptor blockade, for example using SB-269970, suppresses rapid eye movement (REM) sleep, and similar observations have been made using the 5-HT₇ receptor antagonist JNJ-18038683 in healthy human volunteers (Hedlund, 2009; Bonaventure *et al.*, 2012). However, in these studies neither pharmacological blockade nor genetic knockout of the 5-HT₇ receptor significantly altered the sleep-wake state, suggesting that the therapeutic targeting of 5-HT₇ receptors antagonists for sleep disorder *per se* may not be fruitful.

In accordance with the link between 5-HT₇ receptors and circadian rhythm regulation, both 5-HT₇ receptor knockout and 5-HT₇ receptor blockade are consistently reported to have antidepressant effects in a range of models in rats and mice, and also augment antidepressant effects (Hedlund, 2009; Blattner *et al.*, 2019). In support of the rationale for the use of 5-HT₇ receptor antagonists in the treatment of depression, in animal models the antidepressant efficacy of a number of drugs such as desipramine and reboxetine, and certain antipsychotic agents including amisulpiride, was found to be 5-HT₇ receptor-dependent (Blattner *et al.*, 2019). Moreover, other antidepressant and antipsychotic drugs (tricyclics, lurasidone, aripiprazole, etc) in clinical use have 5-HT₇ receptor antagonist properties.

This encouraging preclinical data led to a clinical trial of JNJ-18038683, in major depression (Bonaventure *et al.*, 2012). Although the latter study found that JNJ-18038683 was well-tolerated, it

was inconclusive regarding the potential efficacy of the drug in depression due to a failure of the positive control. As yet, there appears to be no further reports of clinical trials of 5-HT₇ compounds in major depression. Interestingly, the Bonaventure study used REM as a biomarker of successful target engagement. Attempts to develop 5-HT₇ PET radioligands are making progress, and the availability of a ligand for human use looks imminent (L'Estrade *et al.*, 2019). The emergence of a suitable 5-HT₇ PET radioligand will be important for establishing occupancy of 5-HT₇ receptor ligands prior to their use in experimental medicine studies and clinical trials. Overall, the full therapeutic potential of the 5-HT₇ receptor remains uncertain. Whilst the majority of the research thus far in this area has focused on antagonists, selective brain penetrant 5-HT₇ receptor agonists are now becoming available as pharmacological tools (Di Pilato *et al.*, 2014) to help further define the function of the 5-HT₇ receptor and open up new therapeutic avenues.

5. Concluding remarks

Our review of 5-HT receptors in 1999 closed on the note that the clinical benefits of discoveries in basic 5-HT neuropharmacology had yet to be fully realized. Since then important therapeutic progress has been made through the use of 5-HT drugs with notable examples of prescribed drugs for the treatment of mood disorder (5-HTT/5-HT_{1A}/5-HT_{1B}/5-HT₃/5-HT₇; vortioxetine), schizophrenia and psychosis (5-HT_{2A}, 5-HT_{1A}; aripiprazole, brexpiprazole, pimvanserin), migraine (5-HT_{1F}; lasmiditan) and eating disorder (5-HT_{2C}; lorcaserin), although there have also been disappointments (eg. 5-HT₆; idalopirdine). It is apparent from these advances that success in the clinical has come about from drugs that target specific 5-HT receptors as well as drugs that target multiple 5-HT (and other) receptors; equally, neither approach guarantees success. Looking forward, groundwork has been laid for the potential therapeutic application of 5-HT drugs (targeting one or many 5-HT receptors) in these and many other areas including impulse control (5-HT_{2A}, 5-HT_{2C}), cognitive decline (5-HT₄, 5-HT₆) and depression and anxiety (5-HT_{2A}, 5-HT₄, 5-HT₇).

It is also not difficult to imagine that clinical advances will eventually come from further investigation of the complexity in 5-HT signaling that is now being revealed, including agonist-dependent signalling of metabotropic 5-HT receptors, 5-HT receptor-interacting proteins, and 5-

HT/glutamate co-release. Perhaps more challenging for the future will be to understand better how 5-HT neurons interact with key neural circuits to generate changes in cognition and behaviour, but this will be facilitated by new genetic tools and technologies that are fast becoming available. Finally, the translation of these and other discoveries in basic 5-HT neuropharmacology will be facilitated by developments in 5-HT PET radioligand tracers and other molecular imaging modalities, not just to establish the level of target engagement by drugs but also for use as tools to investigate the role of 5-HT and 5-HT release mechanisms in the neurobiology of neuropsychiatric disorder.

References

- Adell, A. & Artigas, F. (1998) A microdialysis study of the in vivo release of 5-HT in the median raphe nucleus of the rat. *Br J Pharmacol*, 125, 1361-1367.
- Aguiar, R.P., Soares, L.M., Meyer, E., da Silveira, F.C., Milani, H., Newman-Tancredi, A., Varney, M., Prickaerts, J. & Oliveira, R.M.W. (2020) Activation of 5-HT_{1A} postsynaptic receptors by NLX-101 results in functional recovery and an increase in neuroplasticity in mice with brain ischemia. *Prog Neuropsychopharmacol Biol Psychiatry*, 99, 109832.
- Albert, P.R. & Vahid-Ansari, F. (2019) The 5-HT_{1A} receptor: Signaling to behavior. *Biochimie*, 161, 34-45.
- Anastasio, N.C., Stutz, S.J., Fink, L.H., Swinford-Jackson, S.E., Sears, R.M., DiLeone, R.J., Rice, K.C., Moeller, F.G. & Cunningham, K.A. (2015) Serotonin (5-HT) 5-HT_{2A} receptor (5-HT_{2AR}):5-HT_{2CR} imbalance in medial prefrontal cortex associates with motor impulsivity. *ACS Chem Neurosci*, 6, 1248-1258.
- Andrade, R. (2006) Electrophysiological properties of G α s-coupled 5-HT receptors (5-HT₄, 5-HT₆, 5-HT₇). In Roth, B.L. (ed) *The serotonin receptors; from molecular pharmacology to human therapeutics*. Humana Press, pp. 481-494.
- Andrade R, Barnes NM, Baxter G, Bockaert J, Branchek T, Butler A, Cohen ML, Dumuis A, Eglen RM, Göthert M, Hamblin M, Hamon M, Hartig PR, Hen R, Hensler J, Herrick-Davis K, Hills R, Hoyer D, Humphrey PPA, Latté KP, Maroteaux L, Martin GR, Middlemiss DN, Mylecharane E, Neumaier J, Peroutka SJ, Peters JA, Roth B, Saxena PR, Sharp T, Sleight A, Villalon CM, Yocca F (2019) 5-Hydroxytryptamine receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide to Pharmacology Available from: <https://doi.org/10.2218/gtopdb/F1/2019.4>.

Andrade, R. & Beck, S.G. (2010) Cellular effects of serotonin in the CNS. In Muller C.P., J.B.L. (ed) Handbook of the behavioral neurobiology of serotonin. Elsevier, pp. 219-232.

Andrade, R. & Chaput, Y. (1991) 5-Hydroxytryptamine₄-like receptors mediate the slow excitatory response to serotonin in the rat hippocampus. *J Pharmacol Exp Ther*, 257, 930-937.

Ansorge, M.S., Zhou, M., Lira, A., Hen, R. & Gingrich, J.A. (2004) Early-life blockade of the 5-HT transporter alters emotional behavior in adult mice. *Science*, 306, 879-881.

Antoniadou, I., Kouskou, M., Arsiwala, T., Singh, N., Vasudevan, S.R., Fowler, T., Cadirci, E., Churchill, G.C. & Sharp, T. (2018) Ebselen has lithium-like effects on central 5-HT_{2A} receptor function. *Br J Pharmacol*, 175, 2599-2610.

Arnt, J., Bang-Andersen, B., Grayson, B., Bymaster, F.P., Cohen, M.P., DeLapp, N.W., Giethlen, B., Kreilgaard, M., McKinzie, D.L., Neill, J.C., Nelson, D.L., Nielsen, S.M., Poulsen, M.N., Schaus, J.M. & Witten, L.M. (2010) Lu AE58054, a 5-HT₆ antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats. *Int J Neuropsychopharmacol*, 13, 1021-1033.

Artigas, F., Bortolozzi, A. & Celada, P. (2018) Can we increase speed and efficacy of antidepressant treatments? Part I: General aspects and monoamine-based strategies. *Eur Neuropsychopharmacol*, 28, 445-456.

Atri, A., Frolich, L., Ballard, C., Tariot, P.N., Molinuevo, J.L., Boneva, N., Windfeld, K., Raket, L.L. & Cummings, J.L. (2018) Effect of idalopirdine as adjunct to cholinesterase inhibitors on change in cognition in patients with Alzheimer disease: three randomized clinical trials. *JAMA*, 319, 130-142.

Bacon, W.L. & Beck, S.G. (2000) 5-Hydroxytryptamine(7) receptor activation decreases slow afterhyperpolarization amplitude in CA3 hippocampal pyramidal cells. *J Pharmacol Exp Ther*, 294, 672-679.

Barkus, C., Ferland, J.N., Adams, W.K., Churchill, G.C., Cowen, P.J., Bannerman, D.M., Rogers, R.D., Winstanley, C.A. & Sharp, T. (2018) The putative lithium-mimetic ebselen reduces impulsivity in rodent models. *J Psychopharmacol*, 32, 1018-1026.

Barnes NM, Ahern GP, Becamel C, Bockaert J, Camilleri M, Chaumont-Dubel S, Claeysen S, Cunningham KA, Fone KC, Gershon M, Di Giovanni G, Goodfellow NM, Halberstadt A, Hartley RM, Hassaine G, Herrick-Davis K, Hovius R, Klein MT, Lacivita E, Lambe EK, Leopoldo M, Levy FO, Lummis SRC, Marin P, Maroteaux L, McCreary AC, Nelson DL, Neumaier JF, Newman-Tancredi A, Nury H, Roberts A, Roth BL, Roumier A, Sanger GJ, Teitler M, Sharp T, Villalón CM, Vogel H, Watts SW, Hoyer D (2020) International Union of Basic and Clinical Pharmacology. XXX: Classification of receptors for 5-hydroxytryptamine; pharmacology and function. *Pharmacol Rev* (in press).

Barnes, N.M., Hales, T.G., Lummis, S.C. & Peters, J.A. (2009) The 5-HT₃ receptor--the relationship between structure and function. *Neuropharmacology*, 56, 273-284.

Barnes, N.M. & Sharp, T. (1999) A review of central 5-HT receptors and their function. *Neuropharmacology*, 38, 1083-1152.

Bechtholt, A.J., Smith, K., Gaughan, S. & Lucki, I. (2008) Sucrose intake and fasting glucose levels in 5-HT(1A) and 5-HT(1B) receptor mutant mice. *Physiol Behav*, 93, 659-665.

Becker, G., Bolbos, R., Costes, N., Redoute, J., Newman-Tancredi, A. & Zimmer, L. (2016) Selective serotonin 5-HT_{1A} receptor biased agonists elicit distinct brain activation patterns: a pharmacMRI study. *Sci Rep*, 6, 26633.

Beliveau, V., Ganz, M., Feng, L., Ozenne, B., Hojgaard, L., Fisher, P.M., Svarer, C., Greve, D.N. & Knudsen, G.M. (2017) A High-Resolution In Vivo Atlas of the Human Brain's Serotonin System. *J Neurosci*, 37, 120-128.

Belmer, A. & Maroteaux, L. (2019) Regulation of raphe serotonin neurons by serotonin 1A and 2B receptors. *Neuropsychopharmacology*, 44, 218-219.

Bennett, D.A. (2018) Lack of Benefit With Idalopirdine for Alzheimer Disease: Another Therapeutic Failure in a Complex Disease Process. *JAMA*, 319, 123-125.

Bentley, K.R. & Barnes, J.M. (1995) Therapeutic potential of 5-HT₃ receptor antagonists in neuropsychiatric disorders. *CNS Drugs*, 3, 363-392.

Berendsen, H.H. & Broekkamp, C.L. (1990) Behavioural evidence for functional interactions between 5-HT-receptor subtypes in rats and mice. *Br J Pharmacol*, 101, 667-673.

Berg, K.A., Dunlop, J., Sanchez, T., Silva, M. & Clarke, W.P. (2008) A conservative, single-amino acid substitution in the second cytoplasmic domain of the human serotonin_{2C} receptor alters both ligand-dependent and -independent receptor signaling. *J Pharmacol Exp Ther*, 324, 1084-1092.

Berg, K.A., Maayani, S., Goldfarb, J., Scaramellini, C., Leff, P. & Clarke, W.P. (1998) Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus. *Mol Pharmacol*, 54, 94-104.

Berger, M. & Tecott, L.H. (2006) Serotonin system gene knockouts: a story of mice with implications for man. In Roth, B.L. (ed) *The serotonin receptors; from molecular pharmacology to human therapeutics*. Humana Press, pp. 537-575.

Betry, C., Overstreet, D., Haddjeri, N., Pehrson, A.L., Bundgaard, C., Sanchez, C. & Mork, A. (2015) A 5-HT₃ receptor antagonist potentiates the behavioral, neurochemical and electrophysiological actions of an SSRI antidepressant. *Pharmacol Biochem Behav*, 131, 136-142.

Birnstiel, S. & Beck, S.G. (1995) Modulation of the 5-hydroxytryptamine₄ receptor-mediated response by short-term and long-term administration of corticosterone in rat CA1 hippocampal pyramidal neurons. *J Pharmacol Exp Ther*, 273, 1132-1138.

Blattner, K.M., Canney, D.J., Pippin, D.A. & Blass, B.E. (2019) Pharmacology and therapeutic potential of the 5-HT₇ receptor. *ACS Chem Neurosci*, 10, 89-119.

Bocchio, M., McHugh, S.B., Bannerman, D.M., Sharp, T. & Capogna, M. (2016) Serotonin, amygdala and fear: assembling the puzzle. *Front Neural Circuits*, 10, 24.

Bockaert, J., Claeyssen, S., Compan, V. & Dumuis, A. (2011) 5-HT₄ receptors, a place in the sun: act two. *Curr Opin Pharmacol*, 11, 87-93.

Bockaert, J., Claeyssen, S., Dumuis, A. & Marin, P. (2010) Classification and signaling characteristics of 5-HT receptors. In Muller C.P., J.B.L. (ed) *Handbook of the behavioural neurobiology of serotonin*. Elsevier, pp. 103-122.

Boddeke, H.W. & Kalkman, H.O. (1990) Zaccopride and BRL 24924 induce an increase in EEG-energy in rats. *Br J Pharmacol*, 101, 281-284.

Bonaventure, P., Dugovic, C., Kramer, M., De Boer, P., Singh, J., Wilson, S., Bertelsen, K., Di, J., Shelton, J., Aluisio, L., Dvorak, L., Fraser, I., Lord, B., Nepomuceno, D., Ahnaou, A., Drinkenburg, W., Chai, W., Dvorak, C., Sands, S., Carruthers, N. & Lovenberg, T.W. (2012) Translational evaluation of JNJ-18038683, a 5-hydroxytryptamine type 7 receptor antagonist, on rapid eye movement sleep and in major depressive disorder. *J Pharmacol Exp Ther*, 342, 429-440.

Bonaventure, P., Voorn, P., Luyten, W.H., Jurzak, M., Schotte, A. & Leysen, J.E. (1998) Detailed mapping of serotonin 5-HT_{1B} and 5-HT_{1D} receptor messenger RNA and ligand binding sites in guinea-pig brain and trigeminal ganglion: clues for function. *Neuroscience*, 82, 469-484.

Boothman, L.J., Mitchell, S.N. & Sharp, T. (2006) Investigation of the SSRI augmentation properties of 5-HT₂ receptor antagonists using in vivo microdialysis. *Neuropharmacology*, 50, 726-732.

Bortolozzi, A., Castane, A., Semakova, J., Santana, N., Alvarado, G., Cortes, R., Ferres-Coy, A., Fernandez, G., Carmona, M.C., Toth, M., Perales, J.C., Montefeltro, A. & Artigas, F. (2012) Selective siRNA-mediated suppression of 5-HT_{1A} autoreceptors evokes strong anti-depressant-like effects. *Mol Psychiatry*, 17, 612-623.

Brady, C.A., Dover, T.J., Massoura, A.N., Princivale, A.P., Hope, A.G. & Barnes, N.M. (2007) Identification of 5-HT_{3A} and 5-HT_{3B} receptor subunits in human hippocampus. *Neuropharmacology*, 52, 1284-1290.

Brenchat, A., Rocasalbas, M., Zamanillo, D., Hamon, M., Vela, J.M. & Romero, L. (2012) Assessment of 5-HT₇ receptor agonists selectivity using nociceptive and thermoregulation tests in knockout versus wild-type Mice. *Adv Pharmacol Sci*, 312041.

Brodsky, M., Gibson, A.W., Smirnov, D., Nair, S.G. & Neumaier, J.F. (2016) Striatal 5-HT₆ receptors regulate cocaine reinforcement in a pathway-selective manner. *Neuropsychopharmacology*, 41, 2377-2387.

Brouard, J.T., Schweimer, J.V., Houlton, R., Burnham, K.E., Queree, P. & Sharp, T. (2015) Pharmacological evidence for 5-HT₆ receptor modulation of 5-HT neuron firing in vivo. *ACS Chem Neurosci*, 6, 1241-1247.

Bruinvels, A.T., Landwehrmeyer, B., Gustafson, E.L., Durkin, M.M., Mengod, G., Branchek, T.A., Hoyer, D. & Palacios, J.M. (1994) Localization of 5-HT_{1B}, 5-HT_{1D} α , 5-HT_{1E} and 5-HT_{1F} receptor messenger RNA in rodent and primate brain. *Neuropharmacology*, 33, 367-386.

Burnham, K.E., Baxter, M.G., Bainton, J.R., Southam, E., Dawson, L.A., Bannerman, D.M. & Sharp, T. (2010) Activation of 5-HT₆ receptors facilitates attentional set shifting. *Psychopharmacology*, 208, 13-21.

Carhart-Harris, R.L., Bolstridge, M., Rucker, J., Day, C.M., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J.A., Forbes, B., Feilding, A., Taylor, D., Pilling, S., Curran, V.H. & Nutt, D.J. (2016) Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. *Lancet Psychiatry*, 3, 619-627.

Chaumont-Dubel, S., Dupuy, V., Bockaert, J., Becamel, C. & Marin, P. (2019) The 5-HT₆ receptor interactome: New insight in receptor signaling and its impact on brain physiology and pathologies. *Neuropharmacology*, 107839, [Epub ahead of print]

Cheng, J., McCorvy, J.D., Giguere, P.M., Zhu, H., Kenakin, T., Roth, B.L. & Kozikowski, A.P. (2016) Design and discovery of functionally selective serotonin 2C (5-HT_{2C}) receptor agonists. *J Med Chem*, 59, 9866-9880.

Claeysen, S., Bockaert, J. & Giannoni, P. (2015) Serotonin: A new hope in Alzheimer's disease? *ACS Chem Neurosci*, 6, 940-943.

Compan, V., Zhou, M., Grailhe, R., Gazzara, R.A., Martin, R., Gingrich, J., Dumuis, A., Brunner, D., Bockaert, J. & Hen, R. (2004) Attenuated response to stress and novelty and hypersensitivity to seizures in 5-HT₄ receptor knock-out mice. *J Neurosci*, 24, 412-419.

Costall, B. & Naylor, R.J. (1992) Anxiolytic potential of 5-HT₃ receptor antagonists. *Pharmacol Toxicol*, 70, 157-162.

Cremers, T.I., Rea, K., Bosker, F.J., Wikstrom, H.V., Hogg, S., Mork, A. & Westerink, B.H. (2007) Augmentation of SSRI effects on serotonin by 5-HT_{2C} antagonists: mechanistic studies. *Neuropsychopharmacology*, 32, 1550-1557.

Daubert, E.A. & Condron, B.G. (2010) Serotonin: a regulator of neuronal morphology and circuitry. *Trends Neurosci*, 33, 424-434.

Dawson, L.A. & Watson, J.M. (2009) Vilazodone: a 5-HT_{1A} receptor agonist/serotonin transporter inhibitor for the treatment of affective disorders. *CNS Neurosci Ther*, 15, 107-117.

de Jong, I.E.M. & Mork, A. (2017) Antagonism of the 5-HT₆ receptor - Preclinical rationale for the treatment of Alzheimer's disease. *Neuropharmacology*, 125, 50-63.

de Paulis, T. (2001) M-100907 (Aventis). *Curr Opin Investig Drugs*, 2, 123-132.

Descarries, L., Cornea-Herbert, V. & Riad, M. (2006) Cellular and subcellular localization of serotonin receptors in the central nervous system. In Roth, B.L. (ed) *The serotonin receptors; from molecular pharmacology to human therapeutics*. Humana Press, pp. 277-317.

Devroye, C., Cathala, A., Piazza, P.V. & Spampinato, U. (2018) The central serotonin_{2B} receptor as a new pharmacological target for the treatment of dopamine-related neuropsychiatric disorders: Rationale and current status of research. *Pharmacol Ther*, 181, 143-155.

Di Giovanni, G. & De Deurwaerdere, P. (2016) New therapeutic opportunities for 5-HT_{2C} receptor ligands in neuropsychiatric disorders. *Pharmacol Ther*, 157, 125-162.

Di Pilato, P., Niso, M., Adriani, W., Romano, E., Travaglini, D., Berardi, F., Colabufo, N.A., Perrone, R., Laviola, G., Lacivita, E. & Leopoldo, M. (2014) Selective agonists for serotonin 7 (5-HT₇) receptor and their applications in preclinical models: an overview. *Rev Neurosci*, 25, 401-415.

Diaz, S.L., Doly, S., Narboux-Neme, N., Fernandez, S., Mazot, P., Banas, S.M., Boutourlinsky, K., Moutkine, I., Belmer, A., Roumier, A. & Maroteaux, L. (2012) 5-HT_{2B} receptors are required for serotonin-selective antidepressant actions. *Mol Psychiatry*, 17, 154-163.

Done, C.J. & Sharp, T. (1992) Evidence that 5-HT₂ receptor activation decreases noradrenaline release in rat hippocampus in vivo. *Br J Pharmacol*, 107, 240-245.

Engel, G., Gothert, M., Hoyer, D., Schlicker, E. & Hillenbrand, K. (1986) Identity of inhibitory presynaptic 5-hydroxytryptamine (5-HT) autoreceptors in the rat brain cortex with 5-HT_{1B} binding sites. *Naunyn Schmiedeberg's Arch Pharmacol*, 332, 1-7.

Erlander, M.G., Lovenberg, T.W., Baron, B.M., de Lecea, L., Danielson, P.E., Racke, M., Slone, A.L., Siegel, B.W., Foye, P.E., Cannon, K. & et al. (1993) Two members of a distinct subfamily of 5-hydroxytryptamine receptors differentially expressed in rat brain. *Proc Natl Acad Sci*, 90, 3452-3456.

Fakhouri, G., Rahimian, R., Dyhrfeld-Johnsen, J., Zirak, M.R. & Beaulieu, J.M. (2019) 5-HT₃ Receptor antagonists in neurologic and neuropsychiatric disorders: the iceberg still lies beneath the surface. *Pharmacol Rev*, 71, 383-412.

Fakhoury, M. (2016) Revisiting the serotonin hypothesis: implications for major depressive disorders. *Mol Neurobiol*, 53, 2778-2786.

Fink, K.B. & Gothert, M. (2007) 5-HT receptor regulation of neurotransmitter release. *Pharmacol Rev*, 59, 360-417.

Fischer, A.G., Jocham, G. & Ullsperger, M. (2015) Dual serotonergic signals: a key to understanding paradoxical effects? *Trends Cogn Sci*, 19, 21-26.

Fisher, R., Hikima, A., Morris, R., Jackson, M.J., Rose, S., Varney, M.A., Depoortere, R. & Newman-Tancredi, A. (2020) The selective 5-HT_{1A} receptor agonist, NLX-112, exerts anti-dyskinetic and anti-parkinsonian-like effects in MPTP-treated marmosets. *Neuropharmacology*, 167, 107997 [Epub ahead of print]

Fletcher, P.J., Tampakeras, M., Sinyard, J. & Higgins, G.A. (2007) Opposing effects of 5-HT_{2A} and 5-HT_{2C} receptor antagonists in the rat and mouse on premature responding in the five-choice serial reaction time test. *Psychopharmacology*, 195, 223-234.

Fox, S.H. (2014) Pimavanserin as treatment for Parkinson's disease psychosis. *Lancet*, 383, 494-496.

Gaddum, J.H. & Picarelli, Z.P. (1957) Two kinds of tryptamine receptor. *Br J Pharmacol Chemother*, 12, 323-328.

Garcia-Garcia, A.L., Meng, Q., Richardson-Jones, J., Dranovsky, A. & Leonardo, E.D. (2016) Disruption of 5-HT_{1A} function in adolescence but not early adulthood leads to sustained increases of anxiety. *Neuroscience*, 321, 210-221.

Garcia-Garcia, A.L., Newman-Tancredi, A. & Leonardo, E.D. (2014) 5-HT_{1A} receptors in mood and anxiety: recent insights into autoreceptor versus heteroreceptor function. *Psychopharmacology*, 231, 623-636.

Gartside, S.E., Umbers, V., Hajos, M. & Sharp, T. (1995) Interaction between a selective 5-HT_{1A} receptor antagonist and an SSRI in vivo: effects on 5-HT cell firing and extracellular 5-HT. *Br J Pharmacol*, 115, 1064-1070.

Gaster, L.M., Blaney, F.E., Davies, S., Duckworth, D.M., Ham, P., Jenkins, S., Jennings, A.J., Joiner, G.F., King, F.D., Mulholland, K.R., Wyman, P.A., Hagan, J.J., Hatcher, J., Jones, B.J., Middlemiss, D.N., Price, G.W., Riley, G., Roberts, C., Routledge, C., Selkirk, J. & Slade, P.D. (1998) The selective 5-HT_{1B} receptor inverse agonist 1'-methyl-5-[[2'-methyl-4'-(5-methyl-1,2, 4-oxadiazol-3-yl)biphenyl-4-yl]carbonyl]-2,3,6,7-tetrahydro- spiro[furo[2,3-f]indole-3,4'-piperidine] (SB-224289) potently blocks terminal 5-HT autoreceptor function both in vitro and in vivo. *J Med Chem*, 41, 1218-1235.

Gaven, F., Pellissier, L.P., Queffeuilou, E., Cochet, M., Bockaert, J., Dumuis, A. & Claeysen, S. (2013) Pharmacological profile of engineered 5-HT₄ receptors and identification of 5-HT₄ receptor-biased ligands. *Brain Res*, 1511, 65-72.

Ge, J. & Barnes, N.M. (1996) 5-HT₄ receptor-mediated modulation of 5-HT release in the rat hippocampus in vivo. *Br J Pharmacol*, 117, 1475-1480.

Gerard, C., Langlois, X., Gingrich, J., Doucet, E., Verge, D., Kia, H.K., Raisman, R., Gozlan, H., el Mestikawy, S. & Hamon, M. (1994) Production and characterization of polyclonal antibodies recognizing the intracytoplasmic third loop of the 5-hydroxytryptamine_{1A} receptor. *Neuroscience*, 62, 721-739.

Gingrich, J.A., Ansorge, M.S., Merker, R., Weisstaub, N. & Zhou, M. (2003) New lessons from knockout mice: The role of serotonin during development and its possible contribution to the origins of neuropsychiatric disorders. *CNS Spectr*, 8, 572-577.

Goadsby, P.J., Wietecha, L.A., Dennehy, E.B., Kuca, B., Case, M.G., Aurora, S.K. & Gaul, C. (2019) Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. *Brain*, 142, 1894-1904.

Goldberg, S.B., Pace, B.T., Nicholas, C.R., Raison, C.L. & Hutson, P.R. (2020) The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis. *Psychiatry Res*, 284, 112749.

Gonzalez, R., Chavez-Pascacio, K. & Meneses, A. (2013) Role of 5-HT_{5A} receptors in the consolidation of memory. *Behav Brain Res*, 252, 246-251.

Gonzalez-Maeso, J., Weisstaub, N.V., Zhou, M., Chan, P., Ivic, L., Ang, R., Lira, A., Bradley-Moore, M., Ge, Y., Zhou, Q., Sealfon, S.C. & Gingrich, J.A. (2007) Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. *Neuron*, 53, 439-452.

Goodfellow, N.M., Bailey, C.D. & Lambe, E.K. (2012) The native serotonin 5-HT(5A) receptor: electrophysiological characterization in rodent cortex and 5-HT(1A)-mediated compensatory plasticity in the knock-out mouse. *J Neurosci*, 32, 5804-5809.

Gothert, M. & Weinheimer, G. (1979) Extracellular 5-hydroxytryptamine inhibits 5-hydroxytryptamine release from rat brain cortex slices. *Naunyn Schmiedebergs Arch Pharmacol*, 310, 93-96.

Graf, M., Jakus, R., Kantor, S., Levay, G. & Bagdy, G. (2004) Selective 5-HT_{1A} and 5-HT₇ antagonists decrease epileptic activity in the WAG/Rij rat model of absence epilepsy. *Neurosci Lett*, 359, 45-48.

Grailhe, R., Waeber, C., Dulawa, S.C., Hornung, J.P., Zhuang, X., Brunner, D., Geyer, M.A. & Hen, R. (1999) Increased exploratory activity and altered response to LSD in mice lacking the 5-HT(5A) receptor. *Neuron*, 22, 581-591.

Gras, C., Herzog, E., Bellenchi, G.C., Bernard, V., Ravassard, P., Pohl, M., Gasnier, B., Giros, B. & El Mestikawy, S. (2002) A third vesicular glutamate transporter expressed by cholinergic and serotonergic neurons. *J Neurosci*, 22, 5442-5451.

Griffiths, R.R., Johnson, M.W., Carducci, M.A., Umbricht, A., Richards, W.A., Richards, B.D., Cosimano, M.P. & Klinedinst, M.A. (2016) Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. *J Psychopharmacol*, 30, 1181-1197.

Gupta, D., Prabhakar, V. & Radhakrishnan, M. (2016) 5HT₃ receptors: Target for new antidepressant drugs. *Neurosci Biobehav Rev*, 64, 311-325.

Hagan, J.J., Price, G.W., Jeffrey, P., Deeks, N.J., Stean, T., Piper, D., Smith, M.I., Upton, N., Medhurst, A.D., Middlemiss, D.N., Riley, G.J., Lovell, P.J., Bromidge, S.M. & Thomas, D.R. (2000) Characterization of SB-269970-A, a selective 5-HT(7) receptor antagonist. *Br J Pharmacol*, 130, 539-548.

Hagena, H. & Manahan-Vaughan, D. (2016) The serotonergic 5-HT₄ receptor: A unique modulator of hippocampal synaptic information processing and cognition. *Neurobiol Learn Mem*, 138, 145-153.

Halberstadt, A.L. (2015) Recent advances in the neuropsychopharmacology of serotonergic hallucinogens. *Behav Brain Res*, 277, 99-120.

Halberstadt, A.L., Chatha, M., Klein, A.K., Wallach, J. & Brandt, S.D. (2020) Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species. *Neuropharmacology*, 107933. [Epub ahead of print]

Handley, S.L. (1995) 5-Hydroxytryptamine pathways in anxiety and its treatment. *Pharmacol Ther*, 66, 103-148.

Hannon, J. & Hoyer, D. (2008) Molecular biology of 5-HT receptors. *Behav Brain Res*, 195, 198-213.

Harrell, A.V. & Allan, A.M. (2003) Improvements in hippocampal-dependent learning and decremental attention in 5-HT(3) receptor overexpressing mice. *Learn Mem*, 10, 410-419.

Hauser, S.R., Hedlund, P.B., Roberts, A.J., Sari, Y., Bell, R.L. & Engleman, E.A. (2014) The 5-HT7 receptor as a potential target for treating drug and alcohol abuse. *Front Neurosci*, 8, 448.

Hazra, R., Guo, J.D., Dabrowska, J. & Rainnie, D.G. (2012) Differential distribution of serotonin receptor subtypes in BNST(ALG) neurons: modulation by unpredictable shock stress. *Neuroscience*, 225, 9-21.

Hedlund, P.B. (2009) The 5-HT7 receptor and disorders of the nervous system: an overview. *Psychopharmacology*, 206, 345-354.

Heisler, L.K., Jobst, E.E., Sutton, G.M., Zhou, L., Borok, E., Thornton-Jones, Z., Liu, H.Y., Zigman, J.M., Balthasar, N., Kishi, T., Lee, C.E., Aschkenasi, C.J., Zhang, C.Y., Yu, J., Boss, O., Mountjoy, K.G., Clifton, P.G., Lowell, B.B., Friedman, J.M., Horvath, T., Butler, A.A., Elmquist, J.K. & Cowley, M.A. (2006) Serotonin reciprocally regulates melanocortin neurons to modulate food intake. *Neuron*, 51, 239-249.

Heisler, L.K., Pronchuk, N., Nonogaki, K., Zhou, L., Raber, J., Tung, L., Yeo, G.S., O'Rahilly, S., Colmers, W.F., Elmquist, J.K. & Tecott, L.H. (2007a) Serotonin activates the hypothalamic-pituitary-adrenal axis via serotonin 2C receptor stimulation. *J Neurosci*, 27, 6956-6964.

Heisler, L.K., Zhou, L., Bajwa, P., Hsu, J. & Tecott, L.H. (2007b) Serotonin 5-HT(2C) receptors regulate anxiety-like behavior. *Genes Brain Behav*, 6, 491-496.

Helboe, L., Egebjerg, J. & de Jong, I.E. (2015) Distribution of serotonin receptor 5-HT6 mRNA in rat neuronal subpopulations: A double in situ hybridization study. *Neuroscience*, 310, 442-454.

Herrik, K.F., Mork, A., Richard, N., Bundgaard, C., Bastlund, J.F. & de Jong, I.E. (2016) The 5-HT6 receptor antagonist idalopirdine potentiates the effects of acetylcholinesterase inhibition on neuronal network oscillations and extracellular acetylcholine levels in the rat dorsal hippocampus. *Neuropharmacology*, 107, 351-363.

Higgins, G.A., Enderlin, M., Haman, M. & Fletcher, P.J. (2003) The 5-HT2A receptor antagonist M100,907 attenuates motor and 'impulsive-type' behaviours produced by NMDA receptor antagonism. *Psychopharmacology*, 170, 309-319.

Higgins, G.A. & Fletcher, P.J. (2015) Therapeutic Potential of 5-HT2C Receptor Agonists for Addictive Disorders. *ACS Chem Neurosci*, 6, 1071-1088.

Higgins, G.A., Fletcher, P.J. & Shanahan, W.R. (2020) Lorcaserin: A review of its preclinical and clinical pharmacology and therapeutic potential. *Pharmacol Ther*, 205, 107417. [Epub ahead of print]

Higgins, G.A., Silenieks, L.B., Altherr, E.B., MacMillan, C., Fletcher, P.J. & Pratt, W.E. (2016) Lorcaserin and CP-809101 reduce motor impulsivity and reinstatement of food seeking behavior in

male rats: Implications for understanding the anti-obesity property of 5-HT_{2C} receptor agonists. *Psychopharmacology*, 233, 2841-2856.

Higgins, G.A., Zeeb, F.D. & Fletcher, P.J. (2017) Role of impulsivity and reward in the anti-obesity actions of 5-HT_{2C} receptor agonists. *J Psychopharmacol*, 31, 1403-1418.

Hioki, H., Nakamura, H., Ma, Y.F., Konno, M., Hayakawa, T., Nakamura, K.C., Fujiyama, F. & Kaneko, T. (2010) Vesicular glutamate transporter 3-expressing nonserotonergic projection neurons constitute a subregion in the rat midbrain raphe nuclei. *J Comp Neurol*, 518, 668-686.

Hirst, W.D., Abrahamsen, B., Blaney, F.E., Calver, A.R., Aloj, L., Price, G.W. & Medhurst, A.D. (2003) Differences in the central nervous system distribution and pharmacology of the mouse 5-hydroxytryptamine-6 receptor compared with rat and human receptors investigated by radioligand binding, site-directed mutagenesis, and molecular modeling. *Mol Pharmacol*, 64, 1295-1308.

Hirst, W.D., Cheung, N.Y., Rattray, M., Price, G.W. & Wilkin, G.P. (1998) Cultured astrocytes express messenger RNA for multiple serotonin receptor subtypes, without functional coupling of 5-HT₁ receptor subtypes to adenylyl cyclase. *Brain Res Mol Brain Res*, 61, 90-99.

Hirst, W.D., Stean, T.O., Rogers, D.C., Sunter, D., Pugh, P., Moss, S.F., Bromidge, S.M., Riley, G., Smith, D.R., Bartlett, S., Heidbreder, C.A., Atkins, A.R., Lacroix, L.P., Dawson, L.A., Foley, A.G., Regan, C.M. & Upton, N. (2006) SB-399885 is a potent, selective 5-HT₆ receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models. *Eur J Pharmacol*, 553, 109-119.

Horisawa, T., Nishikawa, H., Toma, S., Ikeda, A., Horiguchi, M., Ono, M., Ishiyama, T. & Taiji, M. (2013) The role of 5-HT₇ receptor antagonism in the amelioration of MK-801-induced learning and memory deficits by the novel atypical antipsychotic drug lurasidone. *Behav Brain Res*, 244, 66-69.

Howell, L.L. & Cunningham, K.A. (2015) Serotonin 5-HT₂ receptor interactions with dopamine function: implications for therapeutics in cocaine use disorder. *Pharmacol Rev*, 67, 176-197.

Huhn, M., Nikolakopoulou, A., Schneider-Thoma, J., Krause, M., Samara, M., Peter, N., Arndt, T., Backers, L., Rothe, P., Cipriani, A., Davis, J., Salanti, G. & Leucht, S. (2019) Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. *Lancet*, 394, 939-951.

Humphrey, P.P., Hartig, P. & Hoyer, D. (1993) A proposed new nomenclature for 5-HT receptors. *Trends Pharmacol Sci*, 14, 233-236.

Hutcheson, J.D., Setola, V., Roth, B.L. & Merryman, W.D. (2011) Serotonin receptors and heart valve disease--it was meant 2B. *Pharmacol Ther*, 132, 146-157.

Jean, A., Conductier, G., Manrique, C., Bouras, C., Berta, P., Hen, R., Charnay, Y., Bockaert, J. & Compan, V. (2007) Anorexia induced by activation of serotonin 5-HT₄ receptors is mediated by increases in CART in the nucleus accumbens. *Proc Natl Acad Sci*, 104, 16335-16340.

Jones, M.D. & Lucki, I. (2005) Sex differences in the regulation of serotonergic transmission and behavior in 5-HT receptor knockout mice. *Neuropsychopharmacology*, 30, 1039-1047.

Joshi, A., Wang, D-H., Watterson, S., McClean, P.L., Behera, C.K. Sharp, T. & Wong-Lin, KF. (2020)

Opportunities for multiscale computational modelling of serotonergic drug effects in Alzheimer's disease. *Neuropharmacology*, submitted.

Kapoor, V., Provost, A.C., Agarwal, P. & Murthy, V.N. (2016) Activation of raphe nuclei triggers rapid and distinct effects on parallel olfactory bulb output channels. *Nat Neurosci*, 19, 271-282.

- Karila, D., Freret, T., Bouet, V., Boulouard, M., Dallemagne, P. & Rochais, C. (2015) Therapeutic Potential of 5-HT₆ Receptor Agonists. *J Med Chem*, 58, 7901-7912.
- Kassai, F., Schlumberger, C., Kedves, R., Pietraszek, M., Jatzke, C., Lendvai, B., Gyertyan, I. & Danysz, W. (2012) Effect of 5-HT_{5A} antagonists in animal models of schizophrenia, anxiety and depression. *Behav Pharmacol*, 23, 397-406.
- Kelley, S.P., Bratt, A.M. & Hodge, C.W. (2003) Targeted gene deletion of the 5-HT_{3A} receptor subunit produces an anxiolytic phenotype in mice. *Eur J Pharmacol*, 461, 19-25.
- Kendall, I., Slotten, H.A., Codony, X., Burgueno, J., Pauwels, P.J., Vela, J.M. & Fone, K.C. (2011) E-6801, a 5-HT₆ receptor agonist, improves recognition memory by combined modulation of cholinergic and glutamatergic neurotransmission in the rat. *Psychopharmacology*, 213, 413-430.
- Khoury, R., Grysman, N., Gold, J., Patel, K. & Grossberg, G.T. (2018) The role of 5 HT₆-receptor antagonists in Alzheimer's disease: an update. *Expert Opin Investig Drugs*, 27, 523-533.
- Kia, H.K., Miquel, M.C., Brisorgueil, M.J., Daval, G., Riad, M., El Mestikawy, S., Hamon, M. & Verge, D. (1996) Immunocytochemical localization of serotonin_{1A} receptors in the rat central nervous system. *J Comp Neurol*, 365, 289-305.
- Kim, Y., Kim, H., Lee, J., Lee, J.K., Min, S.J., Seong, J., Rhim, H., Tae, J., Lee, H.J. & Choo, H. (2018) Discovery of beta-Arrestin Biased Ligands of 5-HT_{7R}. *J Med Chem*, 61, 7218-7233.
- Koek, W., Jackson, A. & Colpaert, F.C. (1992) Behavioral pharmacology of antagonists at 5-HT_{2/5}-HT_{1C} receptors. *Neurosci Biobehav Rev*, 16, 95-105.

Kucinski, A., de Jong, I.E. & Sarter, M. (2017) Reducing falls in Parkinson's disease: interactions between donepezil and the 5-HT₆ receptor antagonist idalopirdine on falls in a rat model of impaired cognitive control of complex movements. *Eur J Neurosci*, 45, 217-231.

L'Estrade, E.T., Erlandsson, M., Edgar, F.G., Ohlsson, T., Knudsen, G.M. & Herth, M.M. (2019) Towards selective CNS PET imaging of the 5-HT₇ receptor system: Past, present and future. *Neuropharmacology*, 107830. [Epub ahead of print]

Labasque, M., Reiter, E., Becamel, C., Bockaert, J. & Marin, P. (2008) Physical interaction of calmodulin with the 5-hydroxytryptamine_{2C} receptor C-terminus is essential for G protein-independent, arrestin-dependent receptor signaling. *Mol Biol Cell*, 19, 4640-4650.

Ladefoged, L.K., Munro, L., Pedersen, A.J., Lummis, S.C.R., Bang-Andersen, B., Balle, T., Schiott, B. & Kristensen, A.S. (2018) Modeling and mutational analysis of the binding mode for the multimodal antidepressant drug vortioxetine to the human 5-HT_{3A} receptor. *Mol Pharmacol*, 94, 1421-1434.

Lam, D.D., Przydzial, M.J., Ridley, S.H., Yeo, G.S., Rochford, J.J., O'Rahilly, S. & Heisler, L.K. (2008) Serotonin 5-HT_{2C} receptor agonist promotes hypophagia via downstream activation of melanocortin 4 receptors. *Endocrinology*, 149, 1323-1328.

Lamb, E.K. & Aghajanian, G.K. (2006) Electrophysiology of 5-HT_{2A} receptors and relevance for hallucinogen and atypical antipsychotic drug actions. In Roth, B.L. (ed) *The serotonin receptors; from molecular pharmacology to human therapeutics*. Humana Press, pp. 403-418.

Lee, S., Hjerling-Leffler, J., Zagha, E., Fishell, G. & Rudy, B. (2010) The largest group of superficial neocortical GABAergic interneurons expresses ionotropic serotonin receptors. *J Neurosci*, 30, 16796-16808.

Licht, C.L., Kirkegaard, L., Zueger, M., Chourbaji, S., Gass, P., Aznar, S. & Knudsen, G.M. (2010a) Changes in 5-HT₄ receptor and 5-HT transporter binding in olfactory bulbectomized and glucocorticoid receptor heterozygous mice. *Neurochem Int*, 56, 603-610.

Licht, C.L., Knudsen, G.M. & Sharp, T. (2010b) Effects of the 5-HT(4) receptor agonist RS67333 and paroxetine on hippocampal extracellular 5-HT levels. *Neurosci Lett*, 476, 58-61.

Liu, Y., Gibson, A.W., Levinstein, M.R., Lesiak, A.J., Ong, S.E. & Neumaier, J.F. (2019) 5-HT_{1B} receptor-mediated activation of ERK1/2 requires both Gα_q/o and beta-arrestin proteins. *ACS Chem Neurosci*, 10, 3143-3153.

Liu, Z., Zhou, J., Li, Y., Hu, F., Lu, Y., Ma, M., Feng, Q., Zhang, J.E., Wang, D., Zeng, J., Bao, J., Kim, J.Y., Chen, Z.F., El Mestikawy, S. & Luo, M. (2014) Dorsal raphe neurons signal reward through 5-HT and glutamate. *Neuron*, 81, 1360-1374.

Lovenberg, T.W., Baron, B.M., de Lecea, L., Miller, J.D., Prosser, R.A., Rea, M.A., Foye, P.E., Racke, M., Slone, A.L., Siegel, B.W. & et al. (1993) A novel adenylyl cyclase-activating serotonin receptor (5-HT₇) implicated in the regulation of mammalian circadian rhythms. *Neuron*, 11, 449-458.

Lucas, G., Compan, V., Charnay, Y., Neve, R.L., Nestler, E.J., Bockaert, J., Barrot, M. & Debonnel, G. (2005) Frontocortical 5-HT₄ receptors exert positive feedback on serotonergic activity: viral transfections, subacute and chronic treatments with 5-HT₄ agonists. *Biol Psychiatry*, 57, 918-925.

Lucas, G., Rymar, V.V., Du, J., Mnie-Filali, O., Bisgaard, C., Manta, S., Lambas-Senas, L., Wiborg, O., Haddjeri, N., Pineyro, G., Sadikot, A.F. & Debonnel, G. (2007) Serotonin(4) (5-HT(4)) receptor agonists are putative antidepressants with a rapid onset of action. *Neuron*, 55, 712-725.

Madsen, K., Torstensen, E., Holst, K.K., Haahr, M.E., Knorr, U., Frokjaer, V.G., Brandt-Larsen, M., Iversen, P., Fisher, P.M. & Knudsen, G.M. (2015) Familial risk for major depression is associated with lower striatal 5-HT(4) receptor binding. *Int J Neuropsychopharmacol*, 18(1) pii: pyu034.

Madsen, M.K., Fisher, P.M., Burmester, D., Dyssegaard, A., Stenbaek, D.S., Kristiansen, S., Johansen, S.S., Lehel, S., Linnet, K., Svarer, C., Erritzoe, D., Ozenne, B. & Knudsen, G.M. (2019) Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. *Neuropsychopharmacology*, 44, 1328-1334.

Mannoury la Cour, C., El Mestikawy, S., Hanoun, N., Hamon, M. & Lanfumey, L. (2006) Regional differences in the coupling of 5-hydroxytryptamine-1A receptors to G proteins in the rat brain. *Mol Pharmacol*, 70, 1013-1021.

Marek, G.J. (2010) Electrophysiology of serotonin receptors. In Muller C.P., J.B.L. (ed) *Handbook of the behavioral neurobiology of serotonin*. Elsevier, pp. 163-182.

Marek, G.J., Carpenter, L.L., McDougale, C.J. & Price, L.H. (2003) Synergistic action of 5-HT_{2A} antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders. *Neuropsychopharmacology*, 28, 402-412.

Marek, G.J., Martin-Ruiz, R., Abo, A. & Artigas, F. (2005) The selective 5-HT_{2A} receptor antagonist M100907 enhances antidepressant-like behavioral effects of the SSRI fluoxetine. *Neuropsychopharmacology*, 30, 2205-2215.

Maroteaux, L., Ayme-Dietrich, E., Aubertin-Kirch, G., Banas, S., Quentin, E., Lawson, R. & Monassier, L. (2016) New therapeutic opportunities for 5-HT₂ receptor ligands. *Pharmacol Ther*.

Masaki, C., Sharpley, A.L., Cooper, C.M., Godlewska, B.R., Singh, N., Vasudevan, S.R., Harmer, C.J., Churchill, G.C., Sharp, T., Rogers, R.D. & Cowen, P.J. (2016) Effects of the potential lithium-mimetic, ebselen, on impulsivity and emotional processing. *Psychopharmacology*, 233, 2655-2661.

Masson, J., Emerit, M.B., Hamon, M. & Darmon, M. (2012) Serotonergic signaling: multiple effectors and pleiotropic effects. *WIREs Membr Transp Signal*, 1, 685-713.

Matsunaga, S., Fujishiro, H. & Takechi, H. (2019) Efficacy and safety of idalopirdine for Alzheimer's disease: a systematic review and meta-analysis. *Int Psychogeriatr*, 31, 1627-1633.

Mayer, E.A., Berman, S., Derbyshire, S.W.G., Suyenobu, B., Chang, L., Fitzgerald, L., Mandelkern, M., Hamm, L., Vogt, B., Naliboff, B.D. (2002) The effect of the 5-HT₃ receptor antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patients. *Aliment Pharmacol*, 16, 1357-1366.

Mayorga, A.J., Dalvi, A., Page, M.E., Zimov-Levinson, S., Hen, R. & Lucki, I. (2001) Antidepressant-like behavioral effects in 5-hydroxytryptamine(1A) and 5-hydroxytryptamine(1B) receptor mutant mice. *J Pharmacol Exp Ther*, 298, 1101-1107.

McCorvy, J.D., Butler, K.V., Kelly, B., Rechsteiner, K., Karpiak, J., Betz, R.M., Kormos, B.L., Shoichet, B.K., Dror, R.O., Jin, J. & Roth, B.L. (2018a) Structure-inspired design of beta-arrestin-biased ligands for aminergic GPCRs. *Nat Chem Biol*, 14, 126-134.

McCorvy, J.D. & Roth, B.L. (2015) Structure and function of serotonin G protein-coupled receptors. *Pharmacol Ther*, 150, 129-142.

McCorvy, J.D., Wacker, D., Wang, S., Agegnehu, B., Liu, J., Lansu, K., Tribo, A.R., Olsen, R.H.J., Che, T., Jin, J. & Roth, B.L. (2018b) Structural determinants of 5-HT_{2B} receptor activation and biased agonism. *Nat Struct Mol Biol*, 25, 787-796.

McCreary, A.C. & Newman-Tancredi, A. (2015) Serotonin 5-HT_{1A} Receptors and Antipsychotics - An Update in Light of New Concepts and Drugs. *Curr Pharm Des*, 21, 3725-3731.

Medrihan, L., Sagi, Y., Inde, Z., Krupa, O., Daniels, C., Peyrache, A. & Greengard, P. (2017) Initiation of behavioral response to antidepressants by cholecystokinin neurons of the dentate gyrus. *Neuron*, 95, 564-576 e564.

Meltzer, H.Y. & Massey, B.W. (2011) The role of serotonin receptors in the action of atypical antipsychotic drugs. *Curr Opin Pharmacol*, 11, 59-67.

Mendez-David, I., David, D.J., Darcet, F., Wu, M.V., Kerdine-Romer, S., Gardier, A.M. & Hen, R. (2014) Rapid anxiolytic effects of a 5-HT₄ receptor agonist are mediated by a neurogenesis-independent mechanism. *Neuropsychopharmacology*, 39, 1366-1378.

Meneses, A. (2004) Effects of the 5-HT₇ receptor antagonists SB-269970 and DR 4004 in autoshaping Pavlovian/instrumental learning task. *Behav Brain Res*, 155, 275-282.

Meneses, A., Perez-Garcia, G., Ponce-Lopez, T. & Castillo, C. (2011) 5-HT₆ receptor memory and amnesia: behavioral pharmacology--learning and memory processes. *Int Rev Neurobiol*, 96, 27-47.

Mengod, G., Cortés, R., Vilaró, M.T. & Hoyer, D. (2010) Distribution of 5-HT receptors in the central nervous system. In Muller C.P., J.B.L. (ed) *Handbook of the behavioral neurobiology of serotonin*. Elsevier, pp. 123-138.

Mengod, G., Vilaro, M.T., Cortes, R., Lopez-Gimenez, J.F., Raurich, A. & Palacios, J.M. (2006) Chemical neuroanatomy of 5-HT receptor subtypes in the mammalian brain. In Roth, B.L. (ed) *The serotonin receptors; from molecular pharmacology to human therapeutics*. Humana Press, pp. 319-364.

Millan, M.J. (2009) Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs. *Neurotherapeutics*, 6, 53-77.

Millan, M.J., Marin, P., Bockaert, J. & Mannoury la Cour, C. (2008) Signaling at G-protein-coupled serotonin receptors: recent advances and future research directions. *Trends Pharmacol Sci*, 29, 454-464.

Mitchell, E.S. & Neumaier, J.F. (2005) 5-HT₆ receptors: a novel target for cognitive enhancement. *Pharmacol Ther*, 108, 320-333.

Montalbano, A., Corradetti, R. & Mlinar, B. (2015) Pharmacological characterization of 5-HT_{1A} autoreceptor-coupled GIRK channels in rat dorsal raphe 5-HT neurons. *PLoS One*, 10, e0140369.

Morilak, D.A., Garlow, S.J. & Ciaranello, R.D. (1993) Immunocytochemical localization and description of neurons expressing serotonin₂ receptors in the rat brain. *Neuroscience*, 54, 701-717.

Mork, A., Pehrson, A., Brennum, L.T., Nielsen, S.M., Zhong, H., Lassen, A.B., Miller, S., Westrich, L., Boyle, N.J., Sanchez, C., Fischer, C.W., Liebenberg, N., Wegener, G., Bundgaard, C., Hogg, S., Bang-Andersen, B. & Stensbol, T.B. (2012) Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. *J Pharmacol Exp Ther*, 340, 666-675.

Mounsey, I., Brady, K.A., Carroll, J., Fisher, R. & Middlemiss, D.N. (1982) K⁺-evoked [3H]-5-HT release from rat frontal cortex slices: the effect of 5-HT agonists and antagonists. *Biochem Pharmacol*, 31, 49-53.

Murphy, S.E., Wright, L.C., Browning, M., Cowen, P.J. & Harmer, C.J. (2019) A role for 5-HT₄ receptors in human learning and memory. *Psychol Med*, 1-9.

Nautiyal, K.M., Tanaka, K.F., Barr, M.M., Tritschler, L., Le Dantec, Y., David, D.J., Gardier, A.M., Blanco, C., Hen, R. & Ahmari, S.E. (2015) Distinct circuits underlie the effects of 5-HT_{1B} receptors on aggression and impulsivity. *Neuron*, 86, 813-826.

Nautiyal, K.M., Tritschler, L., Ahmari, S.E., David, D.J., Gardier, A.M. & Hen, R. (2016) A lack of serotonin_{1B} autoreceptors results in decreased anxiety and depression-related behaviors. *Neuropsychopharmacology*, 41, 2941-2950.

Nelson, D.L. (2004) 5-HT₅ receptors. *Curr Drug Targets CNS Neurol Disord*, 3, 53-58.

Nelson, D.L., Phebus, L.A., Johnson, K.W., Wainscott, D.B., Cohen, M.L., Calligaro, D.O. & Xu, Y.C. (2010) Preclinical pharmacological profile of the selective 5-HT_{1F} receptor agonist lasmiditan. *Cephalalgia*, 30, 1159-1169.

Newman, A.S., Batis, N., Grafton, G., Caputo, F., Brady, C.A., Lambert, J.J., Peters, J.A., Gordon, J., Brain, K.L., Powell, A.D. & Barnes, N.M. (2013) 5-Chloroindole: a potent allosteric modulator of the 5-HT₃ receptor. *Br J Pharmacol*, 169, 1228-1238.

Newman-Tancredi, A. (2010) The importance of 5-HT_{1A} receptor agonism in antipsychotic drug action: rationale and perspectives. *Curr Opin Investig Drugs*, 11, 802-812.

Newman-Tancredi, A., Varney, M.A. & McCreary, A.C. (2018) Effects of the serotonin 5-HT_{1A} receptor biased agonists, F13714 and F15599, on striatal neurotransmitter levels following L-DOPA administration in hemi-Parkinsonian rats. *Neurochem Res*, 43, 1035-1046.

Niesler, B. (2011) 5-HT₃ receptors: potential of individual isoforms for personalised therapy. *Curr Opin Pharmacol*, 11, 81-86.

Nutt, D. (2016) Psilocybin for anxiety and depression in cancer care? Lessons from the past and prospects for the future. *J Psychopharmacol*, 30, 1163-1164.

Nutt, D., Erritzoe, D. & Carhart-Harris, R. (2020) Psychedelic psychiatry's brave new world. *Cell*, 181, 24-28.

O'Leary, O.F. & Cryan, J.F. (2010) The behavioral genetics of serotonin: relevance to anxiety and depression. In: *Handbook of the Behavioral Neurobiology of Serotonin*. Academic Press, pp 749-791.

Okaty, B.W., Commons, K.G. & Dymecki, S.M. (2019) Embracing diversity in the 5-HT neuronal system. *Nat Rev Neurosci*, 20, 397-424.

Olivier, B., Mos, J., van Oorschot, R. & Hen, R. (1995) Serotonin receptors and animal models of aggressive behavior. *Pharmacopsychiatry*, 28 Suppl 2, 80-90.

Palacios, J.M. (2016) Serotonin receptors in brain revisited. *Brain Res*, 1645, 46-49.

Parker, R.M., Barnes, J.M., Ge, J., Barber, P.C. & Barnes, N.M. (1996) Autoradiographic distribution of [3H]-(S)-zacopride-labelled 5-HT₃ receptors in human brain. *J Neurol Sci*, 144, 119-127.

Parsons, A.A. (1991) 5-HT receptors in human and animal cerebrovasculature. *Trends Pharmacol Sci*, 12, 310-315.

Pitychoutis, P.M., Belmer, A., Moutkine, I., Adrien, J. & Maroteaux, L. (2015) Mice lacking the serotonin Htr2B receptor gene present an antipsychotic-sensitive schizophrenic-like phenotype. *Neuropsychopharmacology*, 40, 2764-2773.

Popik, P., Krawczyk, M., Kuziak, A., Bugno, R., Hogendorf, A., Staron, J. & Nikiforuk, A. (2019) Serotonin type 5A receptor antagonists inhibit D-lysergic acid diethylamide discriminatory cue in rats. *J Psychopharmacol*, 33, 1447-1455.

Powell, A.D., Grafton, G., Roberts, A., Larkin, S., O'Neill, N., Palandri, J., Otvos, R., Cooper, A.J., Ulens, C. & Barnes, N.M. (2016) Novel mechanism of modulation at a ligand-gated ion channel; action of 5-CI-indole at the 5-HT_{3A} receptor. *Br J Pharmacol*, 173, 3467-3479.

Price, G.W., Burton, M.J., Collin, L.J., Duckworth, M., Gaster, L., Gothert, M., Jones, B.J., Roberts, C., Watson, J.M. & Middlemiss, D.N. (1997) SB-216641 and BRL-15572--compounds to pharmacologically discriminate h5-HT_{1B} and h5-HT_{1D} receptors. *Naunyn Schmiedeberg's Arch Pharmacol*, 356, 312-320.

Rebello, T.J., Yu, Q., Goodfellow, N.M., Caffrey Cagliostro, M.K., Teissier, A., Morelli, E., Demireva, E.Y., Chemiakine, A., Rosoklija, G.B., Dwork, A.J., Lambe, E.K., Gingrich, J.A. & Ansorge, M.S. (2014) Postnatal day 2 to 11 constitutes a 5-HT-sensitive period impacting adult mPFC function. *J Neurosci*, 34, 12379-12393.

Riad, M., Garcia, S., Watkins, K.C., Jodoin, N., Doucet, E., Langlois, X., el Mestikawy, S., Hamon, M. & Descarries, L. (2000) Somatodendritic localization of 5-HT_{1A} and preterminal axonal localization of 5-HT_{1B} serotonin receptors in adult rat brain. *J Comp Neurol*, 417, 181-194.

Riad, M., Tong, X.K., el Mestikawy, S., Hamon, M., Hamel, E. & Descarries, L. (1998) Endothelial expression of the 5-hydroxytryptamine_{1B} antimigraine drug receptor in rat and human brain microvessels. *Neuroscience*, 86, 1031-1035.

Richardson-Jones, J.W., Craige, C.P., Guiard, B.P., Stephen, A., Metzger, K.L., Kung, H.F., Gardier, A.M., Dranovsky, A., David, D.J., Beck, S.G., Hen, R. & Leonardo, E.D. (2010) 5-HT_{1A}

autoreceptor levels determine vulnerability to stress and response to antidepressants. *Neuron*, 65, 40-52.

Richardson-Jones, J.W., Craige, C.P., Nguyen, T.H., Kung, H.F., Gardier, A.M., Dranovsky, A., David, D.J., Guiard, B.P., Beck, S.G., Hen, R. & Leonardo, E.D. (2011) Serotonin-1A autoreceptors are necessary and sufficient for the normal formation of circuits underlying innate anxiety. *J Neurosci*, 31, 6008-6018.

Riga, M.S., Sanchez, C., Celada, P. & Artigas, F. (2016) Involvement of 5-HT₃ receptors in the action of vortioxetine in rat brain: Focus on glutamatergic and GABAergic neurotransmission. *Neuropharmacology*, 108, 73-81.

Roberts, A.J., Krucker, T., Levy, C.L., Slanina, K.A., Sutcliffe, J.G. & Hedlund, P.B. (2004) Mice lacking 5-HT receptors show specific impairments in contextual learning. *Eur J Neurosci*, 19, 1913-1922.

Rochais, C., Lecoutey, C., Hamidouche, K., Giannoni, P., Gaven, F., Cem, E., Mignani, S., Baranger, K., Freret, T., Bockaert, J., Rivera, S., Boulouard, M., Dallemagne, P. & Claeysen, S. (2019) Donecopride, a Swiss army knife with potential interest against Alzheimer's disease. *Br J Pharmacol*, [Epub ahead of print]

Rock, P.L., Harmer, C.J., McTavish, S.F., Goodwin, G.M. & Rogers, R.D. (2013) Short-term quetiapine treatment alters the use of reinforcement signals during risky decision-making and promotes the choice of negative expected values in healthy adult males. *J Neurosci*, 33, 15588-15595.

Romero, G., Sanchez, E., Pujol, M., Perez, P., Codony, X., Holenz, J., Buschmann, H. & Pauwels, P.J. (2006) Efficacy of selective 5-HT₆ receptor ligands determined by monitoring 5-HT₆ receptor-mediated cAMP signaling pathways. *Br J Pharmacol*, 148, 1133-1143.

Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S.E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P. & Schmidt, B.L. (2016) Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. *J Psychopharmacol*, 30, 1165-1180.

Ruf, B.M. & Bhagwagar, Z. (2009) The 5-HT_{1B} receptor: a novel target for the pathophysiology of depression. *Curr Drug Targets*, 10, 1118-1138.

Sagi, Y., Medrihan, L., George, K., Barney, M., McCabe, K.A. & Greengard, P. (2019) Emergence of 5-HT_{5A} signaling in parvalbumin neurons mediates delayed antidepressant action. *Mol Psychiatry*, [Epub ahead of print]

Samuels, B.A., Anacker, C., Hu, A., Levinstein, M.R., Pickenhagen, A., Tsetsenis, T., Madronal, N., Donaldson, Z.R., Drew, L.J., Dranovsky, A., Gross, C.T., Tanaka, K.F. & Hen, R. (2015) 5-HT_{1A} receptors on mature dentate gyrus granule cells are critical for the antidepressant response. *Nat Neurosci*, 18, 1606-1616.

Samuels, B.A., Mendez-David, I., Faye, C., David, S.A., Pierz, K.A., Gardier, A.M., Hen, R. & David, D.J. (2016) Serotonin_{1A} and serotonin₄ receptors: essential mediators of the neurogenic and behavioral actions of antidepressants. *Neuroscientist*, 22, 26-45.

Sanchez, C., Asin, K.E. & Artigas, F. (2015) Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. *Pharmacol Ther*, 145, 43-57.

Sangare, A., Dubourget, R., Geoffroy, H., Gallopin, T. & Rancillac, A. (2016) Serotonin differentially modulates excitatory and inhibitory synaptic inputs to putative sleep-promoting neurons of the ventrolateral preoptic nucleus. *Neuropharmacology*, 109, 29-40.

Schechter, L.E., Lin, Q., Smith, D.L., Zhang, G., Shan, Q., Platt, B., Brandt, M.R., Dawson, L.A., Cole, D., Bernotas, R., Robichaud, A., Rosenzweig-Lipson, S. & Beyer, C.E. (2008) Neuropharmacological profile of novel and selective 5-HT₆ receptor agonists: WAY-181187 and WAY-208466. *Neuropsychopharmacology*, 33, 1323-1335.

Scorza, M.C., Llado-Pelfort, L., Oller, S., Cortes, R., Puigdemont, D., Portella, M.J., Perez-Egea, R., Alvarez, E., Celada, P., Perez, V. & Artigas, F. (2012) Preclinical and clinical characterization of the selective 5-HT_{1A} receptor antagonist DU-125530 for antidepressant treatment. *Br J Pharmacol*, 167, 1021-1034.

Sengupta, A., Bocchio, M., Bannerman, D.M., Sharp, T. & Capogna, M. (2017) Control of amygdala circuits by 5-HT neurons via 5-HT and glutamate co-transmission. *J Neurosci*, 37, 1785-1796

Setola, V. & Roth, B.L. (2003) Why mice are neither miniature humans nor small rats: a cautionary tale involving 5-hydroxytryptamine-6 serotonin receptor species variants. *Mol Pharmacol*, 64, 1277-1278.

Shah, U.H. & Gonzalez-Maeso, J. (2019) Serotonin and glutamate interactions in preclinical schizophrenia models. *ACS Chem Neurosci*, 10, 3068-3077.

Sharp, T. (2010) Serotonergic feedback control. In Muller C.P., J.B.L. (ed) *Handbook of the behavioural neurobiology of serotonin*, pp. 233-248.

Sharp, T., Boothman, L., Raley, J. & Queree, P. (2007) Important messages in the 'post': recent discoveries in 5-HT neurone feedback control. *Trends Pharmacol Sci*, 28, 629-636.

Sharp, T., Bramwell, S.R., Clark, D. & Grahame-Smith, D.G. (1989) In vivo measurement of extracellular 5-hydroxytryptamine in hippocampus of the anaesthetized rat using microdialysis: changes in relation to 5-hydroxytryptaminergic neuronal activity. *J Neurochem*, 53, 234-240.

Sharp, T., Umbers, V. & Gartside, S.E. (1997) Effect of a selective 5-HT reuptake inhibitor in combination with 5-HT_{1A} and 5-HT_{1B} receptor antagonists on extracellular 5-HT in rat frontal cortex in vivo. *Br J Pharmacol*, 121, 941-946.

Singh, K., Sona, C., Ojha, V., Singh, M., Mishra, A., Kumar, A., Siddiqi, M.I., Tripathi, R.P. & Yadav, P.N. (2019) Identification of dual role of piperazine-linked phenyl cyclopropyl methanone as positive allosteric modulator of 5-HT_{2C} and negative allosteric modulator of 5-HT_{2B} receptors. *Eur J Med Chem*, 164, 499-516.

Singh, N., Halliday, A.C., Thomas, J.M., Kuznetsova, O.V., Baldwin, R., Woon, E.C., Aley, P.K., Antoniadou, I., Sharp, T., Vasudevan, S.R. & Churchill, G.C. (2013) A safe lithium mimetic for bipolar disorder. *Nat Commun*, 4, 1332.

Sniecikowska, J., Newman-Tancredi, A. & Kolaczowski, M. (2019) From receptor selectivity to functional selectivity: the rise of biased agonism in 5-HT_{1A} receptor drug discovery. *Curr Top Med Chem*, 19, 2393-2420.

Stuivenga, M., Giltay, E.J., Cools, O., Roosens, L., Neels, H. & Sabbe, B. (2019) Evaluation of vilazodone for the treatment of depressive and anxiety disorders. *Expert Opin Pharmacother*, 20, 251-260.

Tassone, A., Madeo, G., Sciamanna, G., Pisani, A. & Bonsi, P. (2010) Electrophysiology of 5-HT₆ receptors. *Int Rev Neurobiol*, 94, 111-128.

Teissier, A., Soiza-Reilly, M. & Gaspar, P. (2017) Refining the role of 5-HT in postnatal development of brain circuits. *Front Cell Neurosci*, 11, 139.

Terry, A.V., Jr., Buccafusco, J.J., Jackson, W.J., Prendergast, M.A., Fontana, D.J., Wong, E.H., Bonhaus, D.W., Weller, P. & Eglen, R.M. (1998) Enhanced delayed matching performance in younger and older macaques administered the 5-HT₄ receptor agonist, RS 17017. *Psychopharmacology*, 135, 407-415.

Thase, M.E., Danchenko, N., Brignone, M., Florea, I., Diamand, F., Jacobsen, P.L. & Vieta, E. (2017) Comparative evaluation of vortioxetine as a switch therapy in patients with major depressive disorder. *Eur Neuropsychopharmacol*, 27, 773-781.

Thomas, D.R., Soffin, E.M., Roberts, C., Kew, J.N., de la Flor, R.M., Dawson, L.A., Fry, V.A., Coggon, S.A., Faedo, S., Hayes, P.D., Corbett, D.F., Davies, C.H. & Hagan, J.J. (2006) SB-699551-A (3-cyclopentyl-N-[2-(dimethylamino)ethyl]-N-[(4'-{[(2-phenylethyl)amino]methyl}-4-biphenyl)methyl]propanamide dihydrochloride), a novel 5-HT_{5A} receptor-selective antagonist, enhances 5-HT neuronal function: Evidence for an autoreceptor role for the 5-HT_{5A} receptor in guinea pig brain. *Neuropharmacology*, 51, 566-577.

Thompson, A.J. & Lummis, S.C. (2013) Discriminating between 5-HT(3)A and 5-HT(3)AB receptors. *Br J Pharmacol*, 169, 736-747.

Traber, J. & Glaser, T. (1987) 5-HT_{1A} receptor-related anxiolytics. *Trends in Pharmacological Sciences*, 8, 432-437.

Trattnig, S.M., Harpsoe, K., Thygesen, S.B., Rahr, L.M., Ahring, P.K., Balle, T. & Jensen, A.A. (2012) Discovery of a novel allosteric modulator of 5-HT₃ receptors: inhibition and potentiation of Cys-loop receptor signaling through a conserved transmembrane intersubunit site. *J Biol Chem*, 287, 25241-25254.

Tritsch, N.X., Granger, A.J. & Sabatini, B.L. (2016) Mechanisms and functions of GABA co-release. *Nat Rev Neurosci*, 17, 139-145.

Vandermaelen, C.P. & Aghajanian, G.K. (1983) Electrophysiological and pharmacological characterization of serotonergic dorsal raphe neurons recorded extracellularly and intracellularly in rat brain slices. *Brain Res*, 289, 109-119.

Vanover, K.E., Weiner, D.M., Makhay, M., Veinbergs, I., Gardell, L.R., Lameh, J., Del Tredici, A.L., Piu, F., Schiffer, H.H., Ott, T.R., Burstein, E.S., Uldam, A.K., Thygesen, M.B., Schlienger, N., Andersson, C.M., Son, T.Y., Harvey, S.C., Powell, S.B., Geyer, M.A., Tolf, B.R., Brann, M.R. & Davis, R.E. (2006) Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist. *J Pharmacol Exp Ther*, 317, 910-918.

Verge, D., Daval, G., Patey, A., Gozlan, H., el Mestikawy, S. & Hamon, M. (1985) Presynaptic 5-HT autoreceptors on serotonergic cell bodies and/or dendrites but not terminals are of the 5-HT_{1A} subtype. *Eur J Pharmacol*, 113, 463-464.

Vidal, B., Bolbos, R., Redoute, J., Langlois, J.B., Costes, N., Newman-Tancredi, A. & Zimmer, L. (2019) Pharmacological MRI to investigate the functional selectivity of 5-HT_{1A} receptor biased agonists. *Neuropharmacology*, 107867, [Epub ahead of print]

Vidal, R., Castro, E., Pilar-Cuellar, F., Pascual-Brazo, J., Diaz, A., Rojo, M.L., Linge, R., Martin, A., Valdizan, E.M. & Pazos, A. (2014) Serotonin 5-HT₄ receptors: A new strategy for developing fast acting antidepressants? *Curr Pharm Des*, 20, 3751-3762.

Vigneault, E., Poirel, O., Riad, M., Prud'homme, J., Dumas, S., Turecki, G., Fasano, C., Mechawar, N. & El Mestikawy, S. (2015) Distribution of vesicular glutamate transporters in the human brain. *Front Neuroanat*, 9, 23.

Vollenweider, F.X. & Komater, M. (2010) The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. *Nat Rev Neurosci*, 11, 642-651.

Wacker, D., Wang, C., Katritch, V., Han, G.W., Huang, X.P., Vardy, E., McCorvy, J.D., Jiang, Y., Chu, M., Siu, F.Y., Liu, W., Xu, H.E., Cherezov, V., Roth, B.L. & Stevens, R.C. (2013) Structural features for functional selectivity at serotonin receptors. *Science*, 340, 615-619.

Walstab, J., Rappold, G. & Niesler, B. (2010) 5-HT(3) receptors: role in disease and target of drugs. *Pharmacol Ther*, 128, 146-169.

Weber, E.T. & Andrade, R. (2010) Htr2a gene and 5-HT(2A) receptor expression in the cerebral cortex studied using genetically modified mice. *Front Neurosci*, 4, 36.

West, P.J., Marcy, V.R., Marino, M.J. & Schaffhauser, H. (2009) Activation of the 5-HT(6) receptor attenuates long-term potentiation and facilitates GABAergic neurotransmission in rat hippocampus. *Neuroscience*, 164, 692-701.

Whale, R., Terao, T., Cowen, P., Freemantle, N. & Geddes, J. (2010) Pindolol augmentation of serotonin reuptake inhibitors for the treatment of depressive disorder: a systematic review. *J Psychopharmacol*, 24, 513-520.

Whitaker-Azmitia, P.M., Clarke, C. & Azmitia, E.C. (1993) Localization of 5-HT_{1A} receptors to astroglial cells in adult rats: implications for neuronal-glial interactions and psychoactive drug mechanism of action. *Synapse*, 14, 201-205.

Wild, C.T., Miszkiel, J.M., Wold, E.A., Soto, C.A., Ding, C., Hartley, R.M., White, M.A., Anastasio, N.C., Cunningham, K.A. & Zhou, J. (2019) Design, synthesis, and characterization of 4-undecylpiperidine-2-carboxamides as positive allosteric modulators of the serotonin (5-HT) 5-HT_{2C} receptor. *J Med Chem*, 62, 288-305.

Wilkinson, D., Windfeld, K. & Colding-Jorgensen, E. (2014) Safety and efficacy of idalopirdine, a 5-HT₆ receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial. *Lancet Neurol*, 13, 1092-1099.

Winstanley, C.A. (2011) The utility of rat models of impulsivity in developing pharmacotherapies for impulse control disorders. *Br J Pharmacol*, 164, 1301-1321.

Winstanley, C.A., Theobald, D.E., Dalley, J.W., Glennon, J.C. & Robbins, T.W. (2004) 5-HT_{2A} and 5-HT_{2C} receptor antagonists have opposing effects on a measure of impulsivity: interactions with global 5-HT depletion. *Psychopharmacology*, 176, 376-385.

Yang, Z., Liu, X., Yin, Y., Sun, S. & Deng, X. (2012) Involvement of 5-HT(7) receptors in the pathogenesis of temporal lobe epilepsy. *Eur J Pharmacol*, 685, 52-58.

Table 1. Summary of selective 5-HT receptor ligands and radioligands. Examples of PET radioligands with proven utility in humans are given. See text and references therein for further details. Readers are specifically directed to comprehensive reviews of 5-HT receptor pharmacology by Andrades *et al*, 2019 and Barnes *et al*, 2020.

5-HT receptor	Agonist	Antagonist	Radioligand for binding studies	PET radioligand
5-HT _{1A}	8-OH-DPAT NLX-101 (F15599)	WAY100635 NAD-299 (robalzotan)	³ H-WAY100635 ³ H-8-OH-DPAT	¹¹ C-WAY100635
5-HT _{1B}	CP94253	SB224289 SB236057	³ H-GR 125,743 ³ H-N-methyl-AZ10419369	¹¹ C-AZ10419369 ¹⁸ F-AZ10419096
5-HT _{1D}	PNU109291	BRL15572 SB714786	³ H-eletriptan ³ H-sumatriptan	
5-HT _{1e}	BRL-54443		³ H-5-HT	
5-HT _{1F}	Lasmiditan LY334370		³ H-LY334370	
5-HT _{2A}	DOI	MDL100907 Pimavanserin	³ H-ketanserin ³ H-fananserin	¹¹ C-Cimbi-36 ¹¹ C-MDL 100,907
5-HT _{2B}	BW723C86 Ro 60-0175	RS127445 LY266097	³ H-LSD	
5-HT _{2C}	Lorcaserin WAY163909	SB242084 RS-102221	³ H-mesulergine	
5-HT ₃	<i>m</i> -chlorophenyl-biguanide SR57227A	Granisetron (s)-Zacopride	³ H-GR65630 ³ H-(s)-Zacopride	

5-HT ₄	RS67333 BIMU 8	SB204070 GR113808	[³ H]-GR113808 [¹²⁵ I]-SB207710	¹¹ C-SB207145
5-HT _{5A}	LSD	SB699551 ASP5736	¹²⁵ I-LSD	
5-HT _{5b}			¹²⁵ I-LSD	
5-HT ₆	WAY181187 WAY208466	SB399885 SB271046	[¹²⁵ I]-SB258585	[¹¹ C]-GSK215083
5-HT ₇	E-55888 AS-19	SB269970 SB258719	[³ H]-SB269970	

Table 2. Canonical and non-canonical signalling, and biased agonism at 5-HT receptors.

Examples of non-canonical signalling are given; see text and references therein for further details.

Abbreviations; Akt - serine/threonine protein kinase, AC - adenylate cyclase, Cdk5 - Cyclin-dependent kinase, ERK - extracellular-signal-regulated kinase, mTOR - mammalian target of rapamycin (serine/threonine protein kinase), PKA - protein kinase A, PLC - phospholipase C, PLA₂ - phospholipase A₂, PLD - phospholipase D.

5-HT receptor	Canonical signalling	Non-canonical signalling	Evidence of biased agonism
5-HT _{1A}	G _{i/o} , AC, PKA	ERK, Small G-proteins	Yes (NLX-112, NLX-101, Sniecikowska et al 2019)
5-HT _{1B}	G _{i/o} , AC, PKA	ERK, Small G-proteins	
5-HT _{1D}	G _{i/o} , AC, PKA		
5-HT _{1e}	G _{i/o} , AC, PKA		
5-HT _{1F}	G _{i/o} , AC, PKA		
5-HT _{2A}	G _{q/11} , PLC	ERK, PLA ₂ , PLD, Src/Akt	Yes (LSD, lisuride; Gonzalez-Maeso et al, 2007)
5-HT _{2B}	G _{q/11} , PLC	ERK, PLA ₂	Yes (LSD, ergotamine; McCorvy et al, 2018b)
5-HT _{2C}	G _{q/11} , PLC	ERK, PLA ₂ , PLD	Yes (DOI; Berg et al, 1998: Compound (+)-7e; Chen et al, 2016)
5-HT ₃	Cation channel		

5-HT ₄	G _s , AC, PKA	ERK	Yes (RS 67333, prucalopride; Gaven et al 2013)
5-HT _{5A}	G _{i/o}		
5-HT _{5b}	G _{i/o}		
5-HT ₆	G _s , AC, PKA	ERK, mTOR, Cdk5	
5-HT ₇	G _s , AC, PKA	ERK, Small G-proteins	Yes (Compound 1g; Kim et al 2018: Compound 2; McCorvy et al 2018a)

Table 3. Summary of some of the main behavioural and cognitive effects currently associated with pharmacological manipulation of 5-HT receptor subtypes in animal models, in comparison with examples of findings in clinical studies (where data are available). See text for further details and references.

5-HT receptor	Pharmacological manipulation	Effects in rodent models	Effects in clinical trials
5-HT _{1A}	Agonist	Antidepressant	Azapirones (eg. buspirone) - antidepressant
		Anxiolytic	Azapirones (eg. buspirone) - anxiolytic
		Procognitive	Lurasidone, aripiprazole and brexpiprazole - antipsychotic (non-selective agents, possible involvement in 5-HT _{2A} as well as other receptors)
		Sexual enhancement	Flibanserin - sexual dysfunction (non-selective, possible 5-HT _{2A} involvement)
		DOPA dyskinesia	
		Analgesia	
		Hyperphagia	
	Antagonist	Neuroprotection	
		Antidepressant	Pindolol - antidepressant augmentation (but note lack of effect of 5-HT _{1A} antagonist DU-125530; Scorza et al, 2012)
5-HT _{1B}	Agonist	Aggression reducing	
		Impulsivity lowering	
	Antagonist	Antidepressant	
		Anxiolytic	
5-HT _{1B/D}	Agonist	Antimigraine	Triptans - antimigraine

5-HT _{1F}	Agonist	Antimigraine	LY334370 - antimigraine Lasmiditan - antimigraine
5-HT _{2A}	Agonist	Psychotomimetic	LSD, psilocybin etc - hallucinogen
		Antidepressant, plasticity enhancing	Psilocybin - antidepressant
	Antagonist	Antipsychotic	Pimvanserin – antipsychotic (but note lack of effect of 5-HT _{2A} antagonist MDL100907; De Paulis, 2001)
		Impulsivity lowering	Quetiapine - impulsivity lowering
		Antidepressant augmentation Sleep	
5-HT _{2B}	Agonist	Antidepressant augmentation	
	Antagonist	Sleep	
		Sensorimotor gating	
5-HT _{2C}	Agonist	Appetite suppression	Lorcaserin - anti-obesity
		Reduced drug seeking behaviour	
		Impulsivity lowering	
		Anxiogenic	
		Anticonvulsant	
	Antagonist	Antidepressant augmentation Anxiolytic	
5-HT ₃	Antagonist	Antiemetic	Palonosetron, granisetron etc - antiemetics Vortioxetine - antidepressant

		Procognitive	with cognition-enhancing properties (possible involvement of 5-HT _{1A/7} receptors)
		Anxiolytic	Alosetron, ondansetron - reduced emotional component of diarrhoea-predominant irritable bowel syndrome with possible central mechanism (Mayer et al 2002)
		Analgesic	
5-HT ₄	Agonist	Procognitive	Prucalopride – cognition-enhancing
		Antidepressant	
	Antagonist	Appetite suppression	
5-HT _{5A}	Agonist	Psychotropic (hallucinogenic)?	
		Antidepressant?	
	Antagonist	Procognitive?	
5-HT ₆	Agonist	Procognitive	
	Antagonist	Procognitive	Lack of effect of idalopirdine and other selective 5-HT ₆ antagonists in Alzheimer's disease
		Appetite suppression	
5-HT ₇	Agonist	Circadian rhythm modulation	
	Antagonist	Antidepressant	Lack of antidepressant effect of selective 5-HT ₇ antagonist JNJ-18038683 (Bonaventure et al, 2012)
		Sleep	Increased REM suppression by JNJ-18038683 (Bonaventure et al, 2012)
		Procognitive	
		Anticonvulsant	
		Analgesic	

Figure legends

Figure 1

Summary of history of 5-HT receptor identification and classification using pharmacological and molecular biological (receptor cloning and sequencing) approaches. Dates are approximate. Figure redrawn from Bockaert et al (2010) where further details can be found.

Figure 2

Possible mechanisms of 5-HT-glutamate co-release and signalling. 5-HT and glutamate may be a) co-packaged in the same synaptic vesicles, b) packaged in distinct synaptic vesicles or c) packaged in distinct synaptic vesicles in separate nerve terminals. In the illustration, both 5-HT and glutamate receptors are located on the same neuron, but neurons may preferentially express receptors for only one of the two transmitters and therefore signal to distinct neuronal circuits. Further complexity is likely through signalling via ionotropic and metabotropic 5-HT and glutamate receptors. Figure taken from (Tritsch *et al.*, 2016) and reworked.

Figure 3

Illustration of 5-HT receptor expression in microcircuitry of the amygdala (basolateral nucleus). a) Green fluorescent protein in the mouse amygdaloid complex expressed in anterograde-tracer labelled 5-HT axons arising from the dorsal raphe nucleus (DRN). Key abbreviations: BA, basal amygdala; BLp, basolateral amygdala posterior portion; BLv, basolateral amygdala ventral portion; BM, basomedial amygdala. b) 5-HT input from the (DRN) innervates pyramidal neurons (PN), and GABA interneurons expressing parvalbumin (PV), somatostatin (SOM), vasoactive intestinal peptide (VIP), cholecystokinin (CCK), neuropeptide Y (NPY) or 5-HT_{3A} receptor subunits. Note the combination of excitatory and inhibitory, metabotropic and ionotropic 5-HT receptors. c) A key interaction may be the excitatory 5-HT input (5-HT_{2A} receptor-mediated) onto PV neurons (green)

which generate synchrony in the network of PNs (black). Figure redrawn from Bocchio et al (2016) where further details can be found.